var title_f23_54_24416="FL with leukemic cells";
var content_f23_54_24416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circulating lymphoma cells in follicular lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two fields of a peripheral blood smear from a patient with follicular lymphoma are shown here. Several cells with a \"notched nucleus\" (centrocytes) are seen; nuclei are partially or completely divided by a characteristic cleft (arrows). The chromatin stains intensely and is compactly clumped. These cells have also been called \"buttock\" cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24416=[""].join("\n");
var outline_f23_54_24416=null;
var title_f23_54_24417="Evaluation of a child with CP";
var content_f23_54_24417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Algorithm for the evaluation of the child with cerebral palsy (CP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 578px; background-image: url(data:image/gif;base64,R0lGODlhIwJCAsQAAP///wAAAIiIiLu7u0RERCIiIpmZmd3d3WZmZjMzMxEREczMzO7u7lVVVXd3d6qqqsDAwICAgNDQ0JCQkDAwMEBAQGBgYPDw8HBwcKCgoODg4BAQECAgILCwsFBQUAAAACH5BAAAAAAALAAAAAAjAkICAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en5YBoqOkpaanqKmqq6ytrq+wsbKztLW2t7gBoKG7vUi6vpLAwcRAw8WNx8jLOMrMiM7P0jDR04PV1tko2Np+3N3g3+B64lEBA2YEAQQsA+VaAuxSBwUBAjXv43bOAQYiBrrimRBY5NwPdy4MAlDo4oECBgvRpUBI4B4WgicEVvSB8IUDeSQM1AuQYICAUQ1M/+TTR4efPwAAU2AcwpBJTRgzVXSEB3JgzycNLI540E8EAgECCgCgJ1TESpZyXP4LyM7BqAWjEBxIIMoBgHgnCcgj4HUEglH+CHANgGDp2poDRhqg59VBAgZnRaUdSaCeggMIk9a7C2BkgQV5AxwwqG4dA3dcFSwYsVjvOcgBJAOIOwrARpJ63Y4asGBtyhEGFIgSgEBeAX8nRbHjLEo0WwBWRWEV1XZE7HWe7xme/JudWt62vaZejXC5PRIDVCswAFDUgRENyvpWCqBB7xFPocLhV+oruwAPfMtrkHKBApMF0C0+MP8EggSeZytuIK/mdAAOLaVAAwVcZxZ+YsFkUP8BAgRWIAP/jVCAVwqdkxQDDCTQIGPfmefUAO6gQ0BbCtxD0T3PJdUdfhEJwGIJZJnlmgFYpSeQAl4h5J2ANapXAlboaNTUhD1qpN8B7AHg3gAxikCRdiSUCNNDG5FAwEvbKRkheOIBIpWCHibFFgMEvSbClRhV5ECHX6kWgFIbzWdmRJSVch1A6bUpCpwmAlNRYDPilRWdESHQG2sdGUoCQZcBY2h9J9IpUmEvnYMkSVhuxhUBiM04qXmQ6jKSXmIiQOZPnwopKG+pGnePnC9dOcCmCyA06zqTiVDfQgdUiR2bv7G5UJd/fBnTTNO5KEKSQGIUl2Z1pucAn0vt157/f5keMGCBi0lLbUd/UiXCawBBlEBb6H14IQMMJtohoyA6SuI9JwUnqVLMMqSiCd6pGB2NAUzGHwBS1rujCcm+KAJWArtaLgDnMtydq9Uiea1E3SGwU8ZR0ktlUwA+B8BR+54QHrFsGEsVhKLc5R5bW3Xl4QgJ/OTZntTOt8BgcBnG1IoMNFbAt35uOPNrMb/ZVl6LiSjbY/Iu2l+8RrVVHVf2GjTpzm9aiJaVey5AD0n/5VUAO9XVY1vAbrqsWod51Rxc0gUsvSfF8yXtldC16sI3dNKlBbKe68CXwskoq4E4DBBinAlWBtpwsAglDzG5FosnfkbmLtiliTur2dBY/wLXxfbeEKNHjrnme3DOOiauvx5G7LJTQnvtXdzugraZ1uHrDBvHMPbgXtj6VxK64746EghACUbwL3zm+AvQe2TzCzfxkNMJHW1Pk/J1JL/CYhDl8bsM1bsQFD7Ta399CR0xoNgv4LeEhAEvglZUdJmltZawx7kNWBTTGAJApAGjQJFINCYX3FzFOUZjEAAg9ADa9A6BoTtHaUSRkgJCpB91o40uktaWAUaOf9OpzvzOxBe/lK5liBnFAWKTgMmAsEMYVMBXYOiZ/1WGLSb04E40RL/6RQUJrAEPvZQipdQE7Uhp88y1FpCUIBUAQxoSwPE+c5r/BChdZ9KOg77CRP9/BGg715Gesih3xQyhqIt94pi2qBifEjTxYzBC24IEILHW0KmP5zkNGhcWsJEZ50gEqSIZsWg0oxAvCOIzIhUiKZPvaK1AKyTgq1Y4gir1gyCK+oqheiO9apFihvUw1a04hZDGJWAudjILKVE0gEu9MpRJNEioCkMKA+RkV5qEURyD86m43MtJSrlJKGHCHWPGSTGJlAcuNTaMoxRRkm+gJArwBx50TKpgeNxVJ+9BlBnKY10MQictRbClKGHJO4kqwEMI1js2YkiC+mJQG/EpkYLp4nLbA2fQQLYRcPGxkANLl8QSOr2kGGiheIMmixK5z0ZC7JHGwOZ4kEC+DzH/czOBs5c4z5TAmd3MMRna0zo3YxiWkSRoYevIYixCG+6IIKUK4Odv0vI0Ql1thG8xpwlQKDhhbqZoOyTJZJhGQxu2rzE6bKpIFfOyo4BEiMCQn+qIoE2NOqGr9nEeDc7HAnbVE3feEwJYvbqEtZaAdzgg6+Fkg83obJWrbG2DW/PKh73ytSB//YRfA6tWwnZisIb9AWITe0TGkmGxjs1mZMeQi8pa9rKYzaxmN8vZzppisqD9XmhHO1nIkva0xTAtale7C9Wy9rWccC1sZ3sJ2dL2tsLArW5fZ9vd+jYRvf2tcAMBgQhEIADGhcBwlysNCJSiA8yN7jJKcQHpWjcY/xUYBQWuy91dTGAUGOiueDshgVEod7zozcQGapPe9lrCAgGogHvnO4kMBGAC9M3vIzQQAAno97+M2C6AB4wI/xL4wAhOsIIXzOAGS9ezEI6whCdM4Qpb+MLspW1wHbw53G6Yw2X4cDZEDGIxkHgaJy7xF1L8DBarmAsunu4RQNc+GWSPGjU2WY4PEuMRezgFH0mBSFq2YxIQMa0rqFCRt6fkhDiOrEiGQfp2cGO1FtkcVzbHj00GnBMQ5SXWZMHp2OdRmdisyS2ostRyMGUdqNkYWU7GljPyvuy8dS05Ao1kzCakvrjDLxiEUmIWsxZ/qFArgzKKDPXnDwuWgNHBgf9pZn6osZAOMEGegZIIk7OsljFggwEQJBkHA5GmDnoEoG5A0z666aQZBIMuM82pdTUKwnTyf+Y5Sa96Wpzg9IWEU1pNqiOSGsrhB9bl++qcfYKCK5WAWe8JkWfQFSTjkO6o6DgbmEhQoSWGJACnUolEUlRGAOmQ294OV7IJckcy1TFvnCRYHKFtEsJkUWFohBDAlnqehr5o1d/M84rUZW+kKKzK3bLSFBW5Lg0VydrX2dEcm/SVgw9A3/R0kbkweoQep9bMKLgcpc5kAHfRSUhOQmrwmjwp/MmQyeP2JiZPyW2Z28sqBWMHMIV6JgGsiQS7nNOVEgMzBL5yzZQqZjL/p2dLWMo86JUaANG1YnR/3GQBjSnKOJ3iS2keCgGtshcv0bJKsVX95AR4gFKmDgWPEwMbGJGgCIhikaPki2ojo7aHqmTQoz46T5csjFfKuUZuA97m7az5R30FuTUK1FnyzNUI/Nmdi2l8IDY92r4ntpA8YX4he5H3DiuvJAvZelHJ9LxR8CO/TG2E8OesKETFLvJlfUdFunwTvU7f9mVzW4aFaYoWZVNLPPs972gXe9+Dx7TAx6YeB6gqCZpv85o+2ubhQk5ViWpSiNnsp5zuDlp2inQzSZVpvvkaDZWSNl1wrR7owOAnv4Z+J6mmHq4vaZp6ajaKrW3Xb0JFX6MQ/wgwT+IXGk/gdsGggGnQOGRQOZDTA3K1ArXnBgzYCxd4Bp4TBqaDDqAjMjwwgSeQOvZzWxn4YlJwgoKFgpOggp7gVm9WB20mByLoZF7ie3CWBNEkBFGWchz4PjFQSjMQg+GDg4oVZ+5jBD14fF+whC1Qg2mGhI2lYTOgN7nGSa4Wf552gCkSNgtRaLZRQhXRD1lBafGwGJPhDo/RQCSQQ0l1GF+oF2Y4hofGhE4BhsB2aadBFlYYE3knaed2U1C1amqYGwFThrgmJiSxFqrHhbQ0bFJVEb/2Flr4UiGidXPggoc1A/SmSG04NZeXRVvER5rhAClBbnIkGZ44FeG2d/9tsSNeFIhk9FCleIreRlGOUy4r520Sp4p15A7RZy1aMgB+aChqOFTgJkvIB0Yz04t0RB/P4UeDpEYvAkg9FHGgWHDuwHF6ZYQsIHRdZwJzcg5TF0oVoUJvckyj8kny4HLWsYN2pRg/ZB3KOBWjsHQftYMwEVQrZ3PrGI4993PgWIxtgXMgY5AgVR+l0or/CC/dZ4601HRKJ3bjKHWkQE14oImxxYmWZzN3d3n2xC6kKHnHBFCuMXgSRTmuoW30lBEFsjDQ4lGTskZlgpKAoQyBZ5KooQCnc3fAuBXfEYE/Mj9qIWoZxyI6mXzbcU8rRUazVyUfeXodIXdTOFsnY4X/28M1XFGJ/ZBSupdUtxF4rsZzz0dVb0MQACER1gc2mQGWerc1Z3lOe6IY/fhRYzkTLGmFN6MA5/KBHeKXc2cQLuU2MBNUDjkTOKVT6sdDVaKVr0Z2wECVcaCRm2BbZjUNThgO3mgEowCEvqAtjYgylKkJo8mCyLOZpgkNqDkFUHgCw5MINMZbRghqwkIz8SaBFlGD2xNk7aCAHTGDLEBEbSeFfVCasHMCBuAVEjNUfMmNopObHLc969ObXwCcLzBmsmmCKiA/JGkWDfAphrgAEARwfDKJyIEaaBFAVlOGiaYg1oFsP3QXhkGQvlYguAZBJBCe0mh+nclSnQFsEGQY/wghQRQEbIsCQ2ZjJYk4hgBoQGDpKuZ5GxA0bOS4h16BbIDTP1d4V2tgnLWlAhRHAhTkgMxIceR5jalIklWSIMCInq1oJbu3cdHSEfSpFhHXFhMnVp0nI+MCMDbCDjjid85Icb8ZEEqhIs6IaoXkRzdBAAtXRw13UD+KokOqHYUXEcDYeAXXMVPibsRJWd6YIbXpnsixkGV3olXyjzDacxXjjtBkMxsxdVgHmVNRNRTZS2WHemOyn9TBHWc4PwOKp7RSpBP0Hkenpv/QTPi4pqAHSl8XdmkqqLjSdHSiJnbTnjuXmWbgobzAnJlClU1yjOz0TugSelA5pk3yTHQRMv8zhG/2ApIjw3r9cIw/eS60V5sVmCxK8S+zR3kVCE/JGE/zVIGz16Tk9KYhySBPaRG/env4mBqnA6tcqkUvOplGyHZyh4YSMnwv9TfrJ3Zj+W39oKplGX1vw6jyV3L315VcASeZYatVMpZ/c1NtwwBjkwBlczfuqTbyGjYpFR/AMFO6ElQHqlSE0kn6d1X8p6/xGlR8Q34KwZJcmCncp6khtpq9AFCZxwStyS9jupHayQwk2IFQ0LEkRRIcuokhm5qOwKmV4LIsC0kYm2RfKgUmG7NOMbMqQIQ9oI8yIIRN6Jk+cLNCYJ2EwrO5o7OHU7M3YLHN5pwXIbS4OTtMuwX/MNuCVUiJB0gY8kcvXghpeUiH7Mkbf5qG4OZobVhS5wCI/lkUieEP4WmgEvK1CyS3dxgaREVp3AaGkogvngaJX1toKpR/jhGHmEg5MZUutjocCzESceN3gvFSY3cYg8YYT4MZMWm1SvuJBLdxWpRGI4kbtkhGKbqKCtKKGvGKJGJGsuhQWRMvyRaL04cfzJik4kghp2G7TuFt7cZkHoOioWhwqFaLC5FuIBOlxUu6wzsZpmhuA0MCE5K8CMAtjTKLGCchFBJzUSptI+IFV5tbMlCR5ThL6PisStGQ7WiY5zQbfyGPsWSnr+tAJTKP0OQmR5pK7NJLI7AqYSkRiCqT/5hkIMh6fUfVK3V3kRJJCuYrdvWYSzaHnveoaBDBv3oHL4DSoxR8tFL3dSaXtCsLA1G5brKXuTn5LifJqjS5kvKQeMnalJCzJQk3Le5UgQ9jqwpRgcf0eK5qEDJcJdLKRu5BkoEXooskkse0vCSgdglSwxU8NRecdMlow4enTibnh1nwvZFwMo7JlQbglRIULMd0l3LZNeYKRO2oEGt5U5HBT4BpfUJzRfUargO7J3r3f4o3KdwnfeCxJyIiFOlKfmAceNVBuA4aeAXLFu6wAOyiFWtRN0pZvWUyF418qauGVXZqxViAxZDQVZe5gFVbO5r8CJTUn2/3ybITyi2Ls/9y9sGqrJqsXANOW7AtYLRBoA5SmwJq150/C7UMrAOxvAK0LANRRrQ2YYQf+D5DRhImccvXJz9FRqizLD4OkWwL08gb0jJbVQChuctGZQIdm5m/bIcjYJ3BrJK9vHUsEM45gMqrjAKgaQJf5kjhjBXADAxGW84t8EsKcCgN0KJOGhKuOgMmS8zpzMzUo03DzMvK9sokIJRt6DwC8bYOpBv4eQ58YRCiOrmYSxxeOLdvQqAK8ABJoRpcu4WUgWc/hCVXWsDKaxRW2p8SNB916IigVzefwbcm0kCbFtFf45Kk9oY25LgtA7nyZIlAhRxZiBDxSc2HTDGQthHPx9F0xdP/CAhYDD0uIGglvTMT97GjYVRzJrdMx8e9CBDEogsdwNBy98uUwduG7fEeOZFEaH0AYqrVhFRtwVcxLuq6XMSmKaJDGyG7QfrEq4cCDqVvZt280Ui9VEPF/4SjktEALFK90XICQLJ3KPK7FZHYDfBwDxnQGXXVNzUnbQgs7MCt9zsmeUrZ8ag60Gwo5YvW9DorsDEWhnKR0BsrAJklaG3SJJeo5hzTiuGmBwCRhFJKwFgR9LtLAoHahu0pCvzIjW3bgYoWFYkQc1rVIeGnTu2BmlS+Ydfc9ttx1/oqUkKVdCfPBBDDmbclO0LZPWSUtCovZo2M5eMi5yYQvPPDy9KR/281IJTTz7fp0oTUMNO2Q6tKeBV13OvUw/fQTpT3p95Seo4TyfXtURYsLryjIzh0MQjR1a3HeUpq4KXk4Bc+exKOG0px2YXF0Ml8GpLJrQSwzCc1NIMpaXAI30QxPf9qcmC8v+06QSLzG7nb03McAF6xPbdCEhvCodykaG+iH6AxQ3NJ12u8Up/Bx/Zife23dzjTfZrnltIdGCjhd2P5ftXLP/hHMNMTN06t5VA9KP3n5R8N5oq1uUWgzjphgHp+A9pcAn2ueC9QOSZQEj5gsQ4NzwaNtLanAoYuWlQ4Be/sAwlgpQbtA7mMdOscZySrg7f8gQrNAjxLggmI561MDv+mfuoZmepVQMRJmA6hDuiXDugZ9qGijRPM/Mvp44DbQAou4LNAoOfQs6JNQcuxvLaM4ZzA3gP4LOineeuDPuvogw0/tw1npQLLfujSLtvdTNA+MgP0HO1F0Oy9B+3bNLZsUYdqYW5UNBsj8UjIZhgHeG5nZDJYgpUMSmtkOzSSi6Hb0TKMCFIaGp7tabiGNigDFMH2OK641hxuUuzvTtVFMaGmERGOG+e68bZzKPD/oZ4lEJ4g/QABuidbCzWAJjM1x7ZWHek0UC45UcMNEK1AGp3aCAyuWydztRqdWEdId9gJI6NoJLB+1G7M6Ltt8m1eKs5ix6J06Tc6KiXmfCD/meYbFmdQLD67M3Mj9+BETK86zKjWU++DFbdx0qZtmIylyUje5o6c6vsPBLsYZfGnKQvlvNHBOG/tEqLb26OPr8F2324Qcu8UqDQmMFfAxE0Qww6dFWMrtFInkSPeJH+mZ0fZ55h5zh1NO6eqemoqrtRog+ooF7l8OIkOCLnyVjkD0Ut4LJL685MACITXUM9OwieVyXjzc3dukgl62OHfgD5RM8LfMwP4M98msetLO0z652uTiJ/2nVQWqroxlxP7KS7Dv5IllH9QEsHeFWfOAqX5CAMb+Pps1FRqtM+mdUlIc88D7MwIJ1OuVVWu/6xF7S7w9uAeTJ2u/3pS51bt/7kPAoEBkEcSBA4gEKQLLEqAsGQxNqj41kAwrFoDmcLAkAUSjNjspSsABahC4NBjnAovA8pAEAAO1UEAQJguXkOUoHYOFLTvwkLa9Q3IpO9Kt5hrMdEIEY3wiR24HKEoATAEgJmhYcEB5HTpmYFluvyQoSC8iI6SlpaWmaaqrrK2ur7CxsrOyqLS3r44RMoeAeH+Ajv5BhMXG48OMRwvu9oyP0NHS9M6Ty8TqFhr/2h3aydke0NXi5ebnzejq6+zt7u/n8LLzzOT09/j5+vP2+/7//tYd6YFwIIGZ3E72KqfwobsGFp7oECZNk7G+DhcOMxUwoSx3hiwOMrjtV3lIP9mTOkNpbQeKl8SI0mLj0hRMi+aFMcSJs9lO0eZQKFCQJwkyuzQeRE0hZg7Li4p6JMkDYETTQqAOfJgAJUdVUEB0LM0FFEqjaBKTUqKZtcRpMYC4ALWABIBCAhiU9NVwFIVZKgouDS0awKrDwBgDVOlrFE8llBE7UoHgQ4xQN4QUJbE6VowkpVa5YZZ2SUlC6w2ULNZQRo7CRbI3XGyJ+1tshqkjjGA6IEjBmKkcZD6aW4Fuwm64E1iQYA0d80IWayFKIAiACRCDzumTINQB1jz9q0cBmsAwkvxsY6dVPcw5UlwYZC3RBVELxTswk0+D7cCLbisUMABYoDxXGKIhGf/3Q/jvVCACh3tVgADWIABSYCm0EROAwQtKCGFAjSSQBsJkELGZQgw51wLGJnzU20vUiPLDXsY0MMNsVXiwoxm1IgcCQiEAp8WYckBBiK9JGBAU5Udsh1iOohgowFAuoDjkKN8sSQKiYzSVRcGhHbAACcQQJUADgRJH5eIuUVASKhkGAQJ3NRw4GIEzfgDlSQwQBlYEO5pl2MGXInlJuTsqGeQdvkJygE5JKnajwgQSgJXmqDjIoybvqIpcTAsiOdv74miH3PHiTJeipasaGQVACBQwETVubWHq2Jyl6acbKpK6gqzupBeraBu1J6OKjzwKgntceVrdfnl5gmch+5K/+eKZN1pwwgdchkfAAmEEsBheBA1YWLcVAqgKBlS9Omp5TKAFYjtJldoJkCuuqEZ4czGqb/BeFqCVUOJKlUTLvS16wtvROWamYolQqClnzWJaxhhSilJAA3rEEoDObE1hcICV4ZUFXOk8a2PltaVcCZx9mCtdptZUbBokC1VQCh+WqZxZoNqoW6wXVBS6AJm3RzAz5dEqcOw92I7VVycrfSv1bgEfLUqR9CbSgIb8WKc1mOzkjXZ/5p9tjoOkKi22za9HTfcctNddz5p2/0S3nnz3TfAfp+9t05gt+IS4KrcZHdNt9wk+OEFOT4NH4mvYngnhNuEeTmWx0I54prPCf82i60sDovns3Au6eglstT441pHvg3oqaR+umN6z87R7DKtvkrpneZ+zO+iDB/6SK9fnTVjSsC1VANwOeBH9CjA1rEmBPhXIVdZKTCudmQYUBoDNTQ6ZWXiu9DoAaM5YZUhLEBRCJE6mGGVdwPHVRcL8kEGmlBBSIFL6mMfCdaznAA8wn2wcpr64OM0EegMKWmQzNGmQBRGGCYtadiMCBr1h/6lz2nXg0JbeNACDo6AK/Tjgx2aQ0HJNC80hIsd8u4miwSFzzus0deydMgc74lrFPGpSiImN4B02ctC8/pWG3yEABLRKUQmoZOHROQEMAggKkR8Vv6O4JcyECA6jyr/zgDmEwQydM0SZCQK2Kg4ISvyqTmEskJqlFioJ94uWJEIQHGCMxwbOCATvJHYXYBjnjpiUQvcQKMp8LhF9UQlOSdMJBf18IVTdSmQqGjPdxbAQ9fV0F/KE5WXIFirUtaICggYnyoZACYmRcKISHoaKho1gxpkUWTcsKWudrmoXgKBDOu71ZzsY8lb7chNY1JaHVoQPfw0qE09GgkQAqUrESUJAR8D2q90Kbo9AsFKfeqYIDkUBTdBSZHhVCcJnmmSXFaiSVBaUw3QJaBXHbNSfGoUAjKBykTNMJSivKGojLUs5Bj0PrUqgoOuc7JYam8FCYikCwTZCBKwQAyHcYAi/w+zxJF41EOJuZx5ikQCaGbxCFgE461M5ZHuuIQ5a3IpqmwSUnO9UwGhUEB57KnRkvrAe3vIBjcM6UBlgIuRMTunUY1XqSC6QKb02ahJaUWKeq6Ti1LQBCanhtR+ItASuqJpz+YkUE6NUltLqQ9q1soEoyBBCSYbpq0c84iccIJp0wTEAqug1xfwjIBzmsJlIrEG68iFCphCRMJQxoJPHIxkKRjZj7YkWGIBlZt85VmVupCQFiIgZ6vMwlLlBFpu+ik2uuIrRlSYI4yeMKtyOQGmWniaKYwWDms9QAVPMICyBuSsMKJhN5LRDtuNgjrCjRtxl+uO5loDHM8NHkYhQ/9d5w4Xu7SBrna7izbvwoS74B3vdsmbEvEC4xPXZUfxXNG7bqRuYTkxLynQS19pMOQA/iEF/zY2X2LA0Rupe6+kgMEHIxqPGsGLrx7zeF8nPFgh/aDEytrZNi88Q2zuIHBFIzc65BaDwXWNcH1JbJB+gOs5o2DbmuYHCRYEUIIa9IECQ6hb/MFYWVObS11uy0epvMbFTeyrCGITkhK6thq2PewIlkcaHYDhC+pLWmbIcILyTK85wrDyxtLg2iHbKRFM0x6Xy9NCvFQ4lPY18THsEUZYpblPMogUNDEKBfL40ZDnsWPm1LgfNpZiiOEAUVS1/Jw6j8yRkYBkJZ3RVS7/0oWVvSmCcg4cUXJVUQAmMkO4hHq5TRNgp7uo060qTWbRoCiIPXizc9fM5mKQQ0tKSwUXpApbBz7BStwUBptoxLlXbmmZZXpUEgygT67Y59bwNKmsjekMfUKsmFLak6VvpyiMgnVSAZoBvaQ1qWTLKczUPvWk9CliNb/6HxBR8UgtEYlII7oHTW3qrklKU841NFkzTRNR8tWCeBPgpxzd10mHhVJHewSlE5ESvBIzuXF1CKdQU+iWaylqSXK6D1YQKblhleo08JDVy3V1uoGxbjyNWjLB1B9yTntae/Y5YZybq2NF6LCwsFxjcdjxkUU2WyX7gcm7ugElFODwAm2J/8oMgNoiGvNpi+OcDTX4xAl6c+Vz8Ufbftpvdlpd8n2Q/Ov3SCh2wy52hJydbG9IQIvLnvZ7mP3tch/H3OUR97rjPSZ5fy4+zg2N0i3O78nRlTFATFC5333v8ViGlvj1CsHfAvD9CHyaS3FnxmnO8O01YWdGTN/EK/54jMdnAv74+MoTQ/KloDzpCoWQzF938xg3FJtBH3oIx0K1pUg2cxgAl8RoBS5Tl99XmnDBJGTQtYaw35N0qwMliCTJFwML+ZzWM0bSQDuAEcz0jV8UJaiPgg7+AvYeYxQYPn/pP2gaClpQPiPThPjMF67tb29WWngLKDr+ASfBMx0t9F8zQf/aRBBAtNSBgBDSv40AdryZMImERokENOlBABoOHlEJlTyCMmzafgEIBQqIbzgYYjzIRmzREonIA4oLGYABJlUgiWBEeoBBpDWgjqGb/Z1D1gAbDSKMsvQeKs1S83VBRinLQ83JNDmGEM5TxWTCB2GCMzgbEEZJCywbztmHAAzHy1ALKmUMN4zTn5BgJPDSEr6BCGSCuUkhElRVlgwhXYFbDdpgv8BCvtUHSRgTuIiVKMTKrCRUDSicfICBvpUWHw6LEoYVHj3Cm4jCwd2hJAnckFTFcCTAuGChdizirfVaEHmLHZIERnyUdiiDIZIhKvhbIxIcpvRhxdDfG7bIDU3/wRxuhJZEwm4pRixiDCFsjCFAWbWck4sxWxUUzRpQASJuASOUwW65wRQMSbIAQQx0WF2JRS1qS1+J1vjlh9P8ogwEIyf4SQKsCDLyXPzd4mLpIPLUn/2V4yxwGD30gAM4nirygzvqxEGkozx8h6fBI9zdYzecYz6aIz9awz76o+IB5N6llclpjojJ3uzRwhHUTECGl0NGQ0GmwjJJTX1tRA8gpKcIXulgGOR13ivM4yoYHiuE5H0NZN5J5O7p1B5IiEVyHmURj0aiXiu4CUxqTUl+HkTSXSwQxZylkUTdx1ZsRlKg0JLQwPf5XvrpwV9sDPfJnC1ax1plnfO4x1Eg/6X5MY9Srp8XVIgCSZ98+UBXbKN2ZMEEoQEemIgIYE/7AUYiyBgKGVmWpQyJnSTeKQ/HkYKKaQsZgBwiXQhGfqB1TNVS9sd/cMca/VsMTkQDtI238VA7ZQMOmeAuQKCFYAqfKcAXrUuFFAgCSktfNsgIquAeGCYQYIWe+SV1YARUvVpd1l1BhtpVtc1JCaWdcRNGigoThiIlYooeJFOPJFsVAJRvGlzKTBuUoMgYCuNlrtMTgqXMoCUqlAs/RWeDYaGuwRwntlLt6eQzpNV3KAkdHgz2qB8JaGJWEdrQTQmJHCJhOuNhEgsfYtFiRkvWPeYDzCbDXRSssOdu1hXMKf/ic+5idX4LpYTVeXJCnHCVr2Sn4wkmXXZnPbAiCqQGcFmKVQQZZLEdNwmClADjbk7iM/7P8IVjBVHBVKLGNlnijOjVhy4ngqVLK27mEZqThg6IVegMgfbmtBhMuMgWG8TVT5qXa86d2SVkOdiaKGSgNSiXKxxphBIp4hUXkULWf2mDHWiYk0bpkEaoT3TplzIOmMKamJJpp5SpyfmDR2LIO83k4CDDlp4dnMYpM9BF+80lLagperDpO9zEk56p6P1pjBzDIxwGAzTAsKBOm5Lknk7XmwaqoD5qLcgCVY7CXalGWc6YjNmWkwGWzV3lmHGe7nHqmPVMjIKFVGIlvaD/qvjoge4BX/dEKqDGqpnGwmMG2husEl+qEWryqkfgUF6SiGQKCKYopFdJpgIUEV/AXGcZamPuhhS9wCc9K1Jp2rMhEBLN6txkazrEwo6sAhZokp1ZybgWSsYkBxqq57iFKjSyybiVatCECUDxUjSFThiWQQ5O2pgg6qzKqdhlja22W1iUiSOcICqAy7yRyqOZq2JQlXo23J7KYUPyCl56hRZE7L3tZ7TWZyf6JrK8CohQ1LYGl8iWzaSiBmKYBLFR6MwkgVtaj8v5wcLq3HSIStEFLC61osQSHY6uVBJMR86aKDf8VVQhDRC0aBnMlSNYJsn269eRnJ/KQ7zsayok/6kxGBfJjizWpsLTNi1HtB/p5CIzSJfWdm26la3WPs7ZcifaiqnamtjejKRG8CThudelRcPm2QHbIo7ecgTWZB6UAM+RXt5H2O0q4KSjbk3cNhixlqnbQijmncLUiuR6TcxMFO4ztBdzoKOVti3fLh4soGp91UoMnaoM6QGnntmPrCBqGBCodKFXRJTDtG7vTY4Che7E0M+rPkCdQoJYhlmZtQaUOQ04Wkfx0S08Om6E/as5nQKUBeDz1ijSBuZvqFoLLGl6Ki1sCIgVApYLas+q3MUjaC8dXSYlMWaCnRS1YKsZ+dOtgFqqDcMLggE0yaAYBWTyPljWAFTk6giUEP+K/w4n0oqKGa7AcBBbpGDTlGzTFBrRsWlBAmtTlEVUpeyvmlDiDwrbArQvxEANtBGrGnIJEbbhPeKvSd5GfaKsTdRKQrFwfZ5ubmqZvkRiqkzHSvLUApCiEfnbr+xUecAoAKKwCwQoyJZKtmVcAEHNo80HDP6KH0abP5ZwTsZCb/VHTshG97FVZVBx1mXM1pUJRbXQCGDSwM0scwJZGoyxI05wIFDBiQ7jZsRRLKFBJlCdk3icwVSPWm4C8RETFHtuiSlEd7DjPFRtiQDLH9MqIneCQaxd27FX2HpNOyry3k7y/VWyH19yFF9y8myyq6kXSYnDQLgD1E6pQHYyM9j/QSgEGPrCZJ6qgkQIaUmowpEebjCIBOUoriloiRbY0ggAW8CWVyY/Qw9kKSuXgivTjqIWwzySckVUQy7HQhvuiaVYJjKr2ylH8/xdlfuJTCcoUA3IZcc8pRREGlAizMAsSa342PPAnFz2ZGNoqvBiApJ5yQv0V1QonybgiH6571ZK0D3vHv5w2WRUhvhJy5Xd6ZJA32okNA1OcyUOlDDXqg8dM/Ne0V+ekPf0gKkYB6D1mrf6mW5YDva+a1DVC071avwu2gJGhQQ6AyMV3HVo0S7E5u9aCGrCdClwNH+Apkw0lLScyFukIKopRToRGQQdymvVhiaTl/76b0UbM8zh/1IrmaubuAQLPIDr/ablHHB4oidV44WB5lqhyFNl4FM1uFOz8QEWBIlN45rIuJPlSZMgsdPr+ujERZVy4rUFp89YpYkHB3Ml/6uuWKgu9lmlGA6ltc29IccRrHJIh8oxK5IhFAqltQB4zptHzMeDapU9yBRnfwGFBAu2WAyejYJMPRpkZ12BmnQm3jXUpU9/CuNDS7OuJEtkul5PMPV4Zc1uWWgqh6BUZ0aQCsJT5sIhSxbBpIrNMYKEBGkLDQfMUo9c9Fwl/JxqgIVrFUkLSQvNcAJoQRZZrIzLPF8i8AyOvra2VRQ2+idtG3UvxwXPbspug9du13Ki9sTX3C82Z/9EssQyMVjzJmMNfws48hJ4gasifXuXgiN4YE8ygzc4T0C420V4gh94hYfehLcalHB4h3v4h4N4iIv4iJN4iZv4iaN4iqv4irN4i7v4i8N4jHs4hv+phtP4jYMdjut42tn4jvs4n/54kL+tkBO5CRf5kdc3kiu5dvX4kju5lz55lB8OBERABARAlUOAlGu53UAAh3fAloO53HD4BYR5matNBegABZj5mo/NBOgABrB5nP+LBOhAlsv5ncPIBqAAnvN5bVhAAFRAnws6TGRAAEzAoCN6RmhAAEhAoju6Qqj5o0s6QDT6pFv6pWN6pmv6pnP64cj4p4N6qIv6qJM6jHf/uj80+RumOpuvej+euj60+u3FepnPuim/ug3hea2Dua6j5K3jOizEF9Quzi1/oUPyupZXQ2yM1OgYDh1nDbETO1iqw32PA+Uibpv5Oj4k+5Bk0X81OyoIuz1E++Jicra/4xZcCaGxkA74iMox9IydM4UCb3Xebv3MhfXobj53GKZCUD+1hRh4GQKt+1SUtFy2zx3ks02Dz81Jy/b9j+5J5el+KiR3H8EEEO6Zu92JArQdEwv6iLOfCGpGK3K8b3VK68LY71FRB3UwWof19HAwWmy2xyUZWsDBHGteNMuzdAojwmiCb2xtoGEOY7OGjsRPWo0gK+OGdEcP7iJnvMaj/3tyeC8BNyNvAomu6UitTJy3VXBdIQK+zlKzVT11cEOzDYF9fIEDl/QFrRKvzRGH8zMHo4IDE2ic4GsAp2uQjM5Wp9mxS/m2Y1TxCsAOd5gGWhy9PQXJQ51jBrHXC6fHmresKANnV/15xnSDcB3Ng9wJUTbFkVSlgDZpL2EMAz2PdqxDjRGxvLC2PKzGxmffPz3Ud9YUtAnSJYGP/CLUnVa889HWZ90WgyWC5Ows4q5S2+jtaLcD+cLAB5lrODcjdFtWJX8dl/YZ1z21zFXQcnHNyjfvK7esxv5DKI7fH5AjVypIc2v4H9f4q02VIs7XSqr6r3+uy//83zn5P7njUP/7e0EzCADiSJbmiaKEkLZPsbTyTNe0QNiBzff+DwwKh8Si8YiU7YArUbP3LAUGQNzRKlsNlrbCIxhNprAm8owrTqvX7Lb7DR+hoSxAuHYXTas5o1lVx2OQEOfXV3Z4VrjI2Oj4CKlkM6AQoGBgEKBpQJCgiQBw4BkAiiMQcDDSVKAJAxAwagBAaSm7QlCQ+XmgSSqq6QBgGkDQRxA84tC70ItQwMKb2tArsBU6CmpQGRAIgIAMMA3LEE4N+BpLsuWpEHMa4PqeENP5CaDr24xfmigZ+Q8woMCBNea0UMBCG4MnxWahagDqQDsBBaiQCFMgGDdhCgAgvKdgYYJUIzL/McDSoAGABQoGUKQSLRqJAF9EYHkWChXFVFp2QAzV7tgJArKEJSCXQIAABTy7XWSxkaK6PQQQsIzhoAGzGAhyNNxC8l6Ak/1M/mlhkKDatWzbpkl7QuarAwyhoWLVy8DZFQwQNHtFBSwqPXTrDOp14GZRomRWOABFgiIpsiJwRkMAuScAvJsGeCIQQ1VRv80wO3GqCioVAwWmisCMDx5rEQNaN4l2WFPiPrl19kPrNrjw4cQV1fi4dCGy2w8h2/y9wiSABKD2OGiNPOSTjAAe6CQUTiUzl4dqt0NxSQD4qsJ0FmDA4Jm1nybov0amnpzN9/FZJH8K2D2tjWCNN1ad/yfCVuF4ZdcB3HmXGHgP+qZDcRZeiKFacJ1AyyViBcBJg7/otpcAIxZQXSuBVeLhE++wcgBLvowSjBkJ9MPANkfJiMAWsKDCADvy7TAiKgS0EpoIg4wgDohBtsJCA041scdsBC5h2juktAcLPQ2+iAqPYO5WYYZmnonmGxumKUOOFjniRQvxGZCjfmy+cmeeeu5ZEJ81OADeIy8kOZMmv925pp+KLnphoow+GpyjkE5K6T+SVoppJJdmymmnb7lhjXot5DHJpmwUeMIeaZw1hI9vFmGqp7LOCkSsQ6Hmmh1OYUHqlSmgCiAYuP46h6qq9lAgsCOwKkRSJTDQpEYq8v9iT6q0XovtEbb6UOALJfA6LG0bKntaIcoa+2qpMjAbREslJHDULISAyNEICpqwbbb66pvWOvC4g+QrrHXlnybzzMKZCAwEkCS1pNSzpcNH4TUgbQmPiAA+BtS2ia64SAbLKF9QmQ7H9JqMBmmo/HgyXkUxaXB8KhJJozA5dCgLypuxkGNNNhm8AGkVM2OnHrIwQ5JcUuzLdNPGlbBFDCldBUBWr6ikq4JdecQCqhVFZszNg4nAywPkfjRfREHV4eEDHXWSyk68sLA1lf5hJ4vbXDskhUVR4d1dR8vGm1SyPonXkhUfKaRAMNbMZmWCDHuTw7EI4yuLMzZ5aK3Tnn//rgeHS1AUW2uqRjdgbTJ5/Sq4OcV4ZGdzrL4DZyAy14uRdWCxhxVUrlaAw7oNdq7fwAs/tje597iENbk4oRcBcq2cijVuJvCygBYHaG/yegS8WfZLg04+0/0uQR3Vcli0goIN5IDcEgsTKqquryNAyMIbj1VC/OE4ZwdkcK5cNtMDFXynGu0NcG+nkEJNqgS4MsRLXOSYj3imoDj/hMR/RhFc96RWuXTBq3rzEp8/yofCa53PYHH7y+kK1qUPeUIE3iIBj5hzAFqwgk6eqJgMaYYYXWyMYvYrYIAQGKDZmKw1upghCUjDC+AhrBUlaBIP4WGNEdXoZiyShS5YobCN/3wLaNwbAV000TiBleB5KMhXCt+IKNGloVdwDIJUZhESR7ixjnzE0PnEUL8+CuEd7poOOBixR0EqMlKLVGQiGwnJgTwykpyaJCUvqUdMvtGSmuykmjxZPk6CcpRiECUp92TKU6pSCLlrpStfCctYynKWtKylLW+Jy1zqcpe87KUsVwnMYJZSmMQspjFTacxkKnNfyFymM59ZSWhKc5pwbCY1r4lNNFkzm9zspnC26c1wijMg4BynOc9ZiHKic53sHGY73+k0DvhynvSspz3vic985nMD8LymOvv5KYBK858CRQJBCwq6gyKUCApdaNMa6tBaRZSPEqlJSiQ6UUamQP8TMchERrFFEQa4LSw9gOhHy9TGAjDRpCcVSFVw8qIFLGAUWGtjS9myJm4gxKNavCmmeJEDqmUlkMDxKUFyqhduHG4lhTQqpJpQugNMA3tFdSo50UInvIQPelZ9KgvUFxkfjgACEYhAAMoKga46gqxmRWuqvKiJ8KzEcmrlk4uaoSUTAgACrexAXRnB19z5FXOVAWIADvlXfuXuAoldRCsZ29hGVqAXFIhsISaricpadpET6AUGNguHzmris6AVpAR6kdbStuG0mkitavm4gbi+tg2xZelsz2SBAFTgtmzI7W55C8cMBGACwFWDcIlb3BRqIAASSK4Ylttc56JQs9L/RQJ1qwu66GLXCNrdrne/C97wipeZ+iyveW/5ufOqd73snWVdbTsc+LZFvsx8byjTS036ElO/88XvNPkbTACvRcACIfCsDHxKBBfYvwO1L/kUrCka0DGF7JKDgxtxhyMd6gTv0EG6aABhSBhkKZpoADnCwKwKl/LDPCBXix2lYjypdcQBwBpO5tgNtxVNTnRNlfF8EOJHzME7shCFSlC84U65+FtJtvCMy6AAD91YDEi2ATNA/OOSMlgEDQAH0SCGAIdl7C++w4YUSuaynb1uC1tIagynsAVWKEAcwdjHNXoxgFCpdBzl0EQ3tOFninnUQFwiRhQdsuMgd3LEzwgJ/0zJuKw9x0sck45Zn8WYk03IIwYgQtEI8OKMBrG5lbxAc8du4UNFN2IOU44GAS64gD+YxStiI+nfPJK3jlgGFVv46uS2Buc9FCAHg1bSWBoAnmALI3g50gtTiugEcBRo0JgZTwFNY5rxdZXROQq11hKxk2bnZzpKIZxSggftAn77alBbwq5zKEZj3Q3XgbPDSLT90Cp6eSxPABEWekMmHM7keKR+97RTZ7o8L6EJjxvFXYqibMVkOwyeIcYCpo2ljA3ICpRQmpO3XYbWvEMAVqoN2CpjAJWRQuWYyUw3rFDyhLe7MqLmAroEhLzC4GvLYilyAo7MAgjVb0IBb9DAFf+YPfacAt6SAyFgCsTw2gUDQhcdT6j6kIuQ9ucEENlCBVEhCqtM7n1O+HnnQP6tAbFCAO4DN9b1MkGj2EnrU1b32EM4czuUgtc2f6AUF5gHVSMSyiU+sTnE1AoKCXx92luiQ37E9J+9WeHlClXiY8QKVlBeMU+CRzdiB4Mn2cYS1FEeLPrgHRYL/pKMNjYMD7ast19aFlZ8kgLqjoVNl1Fc4oI8qqAIwSnCI92h89zqkYC0GczpChs+fiSd71ieT8pHmG6joY5QUZs++cHSXyb0G/n9OIS/DePnU/n7eH7yd58GgyqEg6r/gyUPwUE+A/KFsxCuR6U/oD6I0xYg83//dtALWIMYQOAATaYuRycDrGEwsRFXlLBjKGVVl6IZgNQH7CJ/fWNAQbB/7tQDS/J45OAXoMAe2bd7PSAlRVA8MkBkr1EHYUBVP9CBm4QH+TcEMcY3WAYr6ycD3yAufKEApcce90JXLCMLnRZm2IAPUhUzo5YJA2MyOZMwI6AyiQFpXIZYBCQCViOD98d11PA4f1EkCscOMYAzVbMMeHUzeBEIRERpDDBTJVaFwVaGhZZkM2hQP0AU4sIaAtAVJIhGgVCEGsRu/wMUC9AE41Y48YY1bdMRaFMsVLBuonErJMAJGIV2KLATugIsJoFsBsRmerc3CkETsfcce5N3ilhu/woYbFRQFczwBeyCh9qih0UBFqyAiCSIAEECDkUYGCtjEbYTIqb3CaiyBzlHPJGoPZfDJACUGpaIgBvlhSUwcdWwAwDHRspmINOTGKywi7knPd7De8ToC1N1hMZTILCxcXfIgy3ggw4RcLoIFBCXLtYhc4b4jOM2jtyzQBwkB1/QdiTgHXWAAC/YDVxof9unifwxJJsxdQ9xQZRHaNlhJ+kBHhlkAl4ndyH3Cn6XjmLndNrnNNsCgmChCvLoENRnayrCPUWic7NnjBbheE00B1Cke5GxDQTAPt0QgwmZiSdgew05JguQedpoGjiTIzEjJlzkZyMgerOXV6YXRR9pev/DJo3GBwRxwlAsZiYQiIkTiHziKBz2sXNY+QPtNwQ9Zib0x4HTGH/mQByxc28imW//5Zbm047FNIv3xX1m2WAKmZcHll93WV9+CU172ZcJFZjChJgJ1V6PeV7pBZmTSZn4NF6XGWGYqZmOtJmdyUeN6ZmhmYeiSZqLWZqnmSmgiZqrKYGs6ZrR9JqxmZqyWVyYVZm3iZu5qZuzZAG0ySiqmU3A+ZrC6U++uSjEOZjG6SfIaZfKaX7GyZyoGZ2H6ZzP6ZvTWZrY6UzaWVc4+JWxGSveOUjR+FGnYGM2aANmcApFsZ6vYA7v4Iz4Bp4zoAzsSZ43CG700h77w5LwCU//SyFl6FkD6gkLhXWEecM/KsadypQoOdIQRsQGBCohIGKSgHKK/9loW7dpTggPn2AwmTYO6qlSA/AAR3Kg9QKhdDmfLaANMkERlXAUFMEK8RI7BMAAHApqH2pnIloRJUqhg3FRKcpOIaUA3vZrOhlvdBM8h0Y2NCGiftgAT+iesGARCgqdWRAMiciQ53YA4sYfi1gHG+EMB8CkYkEZkQalT0h90nOh7yQVIxdzMWlEU4CIeSGivNAR9AIiLFETVnqdLSA8ImcMBfl22eaHcso7AwBwd2oJAgMWLdqm7XRHa9d2iNoHU4A/AKA/IhoOUHGibuMOCLigybQm9dMzViAR/9GDcnRnjYyXqETHqSn4o6kAKOQgntl0R5nwehdncwd0qXlWCTvEqXJwosvmnyYgWr0QAa6ZrJqwrCYwZQggJQNoRM9Tozfaq3PqEpc3rEZjknawAtXimsuVO911muTaC+ZanRgiT5rAT6/ZrgHwruuKW73gAbGZW5pwr/R6JsKlCcjlmv46XPx6JhfQCxoQmwarCQhLsGZCAQHAAbT5sBHbsGaCAQHQm7J5sRlbsRjCVxlAmx/bsWYSAJAlmyU7shlCWrS5sinrsi8LszErszNbTbtpszeLs7TESjnLsz3rs65Ul9K1R6P6fEHrXEOrmUQrn8WFtJiptDOBXU17mf9P+3FHy0pJa7TJJbXjRbXF9wi3upVowZW0srV64iqr1LUy9i7hoiUNQFI34HZUNixquT5ga4FaiAgSFqZjq6JahgISwZWc4bZyFAQZWInOsgZ0O6D3+U1Z6yPDch0xQBd8C7dy20Z8q7iFgIM4OGEn1IUcpgmBW2S4EIGGuwZNpUppmxa9ogD1h0e1gA4dowwcZQVasoYdg4RXImd0JnyYkBcUw2npoHsYdLvVd61OSCAXY2Zgdmf58AmJuAxNWowusxBopDF0aAkAc31Q25YbJboj0Lp9NjFU9IY46qEFqmczSg5v+BRCMxOmRi/vNgxnRAzkEGy7CwwfEjEORx7/9lYtTSKglpK1eDsTb7s4IXFrpfgc1qY4uVaIV0IFVulRjkh83BEV7XCkgIGRaQcfYNo/juMTaoOItfYTEhFrxsB2PYYFjqiRBNSKegeLQlq2GngCbKQrqlggOJyk3rCkEcdsFokUn5dAMzFvFCy/X6N1zvLCEowGnphs/fsVOvFsnXtVeGkCrJs93Bh8kvGNRLGOyJguUNc1K5M7OtcXLvSLMafB4fi2hCYMzFMCtLMZuTOM0SCM4BI5J5dzyvAR/SaR6hipavu5l4sCNty6LJeOy2OpoLgDErc8AOKLOFdwX9IHhlodEhl19+BwDkKPSHQZLhdfA1xEZXodMKGT/xQZfOAbPQG5QHQlxnwDeHXGP6VnjwFJvKgYVvDRkP1TMPhYLtFAlvXTPioMHgskOXSBDEYJkguytDyQUxZRps9DFyIXdxqpjzl4RL96dasad5Bcj3+XdHtHJsumy6rxys7zkFIVkZ7sHuUcylZ8JVRUpsQYZmcIQUkZojlAGjcifPfoK/ZjDTO5CaPgab2AxGR0y7RgvIaCrSbwRYalO6/jkjcEQ5OTIJXQIxRDfdmwCcpclf0ww5IXMcciuPpRez0Ek9maqNu8VVbkzRqoRETkI54wzgJYv0+3cGPMJTBClB0KxQ3SeXXXX/A8SndUHGQpyD4JTMnXJjbsFqpb1P9oRLkuxULN3JqjRH022AuMm5mFKbRX67SizFsh/V1Q/ZaZKwQadsVD/AZUzGGHYgYrWMXfyYFTTQSmGwlurUd27cxinQJNgLhpoGOViNZE4Do+ENeNnAhyDRBkDWR8LQTbXBfpydU8UGUzAI5F8DsbOJpe3QOomwTMstkRisI/wCqJTcONDdZh2wbAotdx8Non9xZZRotErbfu26RS9KJ8drw/giAg6mYHs9nXipBGsUY110MN0wzMK75FYzLnpr7brDPv2zEqIwuzOzkPyn+D3APAG7v0wty93WYdSgofKjENjQMaA73/Eoc1dnLMnbx+doYgAy+aMDJmVmb2sA//YsZxXeS/WzICetM9C+GHiGGERmDWNjDaua09rJrE1uiKAGQF6/Y7D643WyMlX6Rm0RA1cmWK4AqPqkgCH7EfXXoJ2wyJUjBvVDgv9afdHsjdP2DBhBjF3djB1himSkqmx1I2km2QQiUlgfLetTbigXDAJ9HDdOMVsOY7RG5sZ4qRClHjTskwrJEYQMc9t7aDtj0DC54Tuj2olkyVpqjGv2PJC1OiDqANhLLhfLcfso1DLGdGyaMYVyfHRzcbJDZ8XByBMK7UNnDG9rAHYBHnkHGoKv2rdSo7BVQXUWWO7210TZo0Y0Mh2VxE/sYgr7OoF8jGhLF4IpAU2COtLDDa/6nMUH59DkVoC4I6j6w65qcYkBW+peFwCSzhQSfZHpFXeoPzy9/R5yRerftTQP64gVZeitcx4rZQ2X3dvR84y5dcNbbxJVu6yICRqfoj2cvBdr8daZD+OkUOvhp0pr2T6UKX6XaczvWDkcnx6RwBClHmJR1Z7GLV7PxCBycoDyJHrTZto69uRLo33AzNEUgRnzPNd1VtLxgtcC5NINugFG+3zTQJ06MHD++hIye27FfN7D1wIimCRfYjE73tqtocrD9aQEK03qQQlabY7gpdDf6dqIz+nueuE5e3lK/bIpEuOVSA7PYDfFK05Z4d2hm/CHitQqvNtaiOn8Jh9GSL9P/ileBWW+9Qr/Sq5djbFfVCBtmmLVslENuycvViK0lbnyeorYlEX1X2ngSxUfDKqAYLw5WkUthff3PvTNcF0TrQEcCsnQR4bThIkGKLrdh5mwRZXwR5rINqcGXngC9kj/d+9PQe1uV7n5aOjwRN3wOBnytv7efYEivWjQJ5LK3RlkX829z+ch5acnFpdhEMDWokAMA7HTSIEVNOuN4Hg4TAO4euyNCoz+ZCFvkFIbw5gN15Nd/h+qBC8WkBc+BjqA4uswVfUHreTd77zDcyOg7nrdGGVSOSVjQYAxJ+pg9kVgAwit7EvwzYX2nj0N419TRq7wOZegJsDxZIMx+/qsP/EW5tIkDBIACIQsEwiTAEIkseACEsygI4DRAMwFzfqkAUWwRqCEIOxwIUHLndk2RCqXYExDKr3XK73tz3uwpvA0ESQIAMPFgxkSJoUDBIu0PggH9pm7lzAUAD0tOSggHAg0KiwmCWnxkAQoGejkoaJcMhC97DJcBlA87MgIsmIksD1gENgdMIIYtBQF0JQ0HKilpO20jmoUACAwBKMFnW2LHyMnOzc/KxgEJAQOCWgbWbgAPWZQGqDgI1NcInAgI25zg1nyRWWjm0u5DA7HigDoA9dcEnTL21Afh2MBBHrtCTcyPiiVDo7KEXecwkHsuXbheJAAgYvNkjIs8uetyW/xQch8VioG8foQDAs+6FuGElD+YLaUkXoW8LCIwz8MkbKgIGQqpkUWCdzwQBCCwIaUApu5BXLmE8upGoAYPkDjQIkAAVGYoQx5Itu0Qsl042As3Kkm7JHAU7Qo3SEWyYCHMIiLDcpEXKrVxZAOPqcbaN4bzJhhQRtGbHrGEJTvayawuXXrNm0YZ9iDJNLACHXME5QyckqAI04NIidhJyIFE88rHwK+JBAQJIIrsuZHMA1ZxZEwBgEMBna7qzSwlfomqLKmNMnDwAiYQVctCGhgq/+zdbGM6ax5OPyIxnNbby9mkUkVsxj6NKd3Slln2egHELBPLLgp4AA/6IcEIACv/gkoZJkkRlkj9v5OdVDfkcAFUBWBiEhxXUAJhZeZ6NJV4Xn6mhCTXC2OPTNJugRkxoLVH4mj6BLCAfbXkdVY0KC9yCwIT8wPhbcO6hWM1xBPazQo8BOIHVEknmgV4BC8yg0YNHHfBgADgER6JXdTRX33FYghVeh2WayQWIZ6q5JpttNpNmiG5+oQlLctp5p51w4rnnR3z6+SegZOlZRqA2EFcoool2pmiggzL6KKTjOYpMpJVayuekl5aVqaadesoCp31+OiqpH5a6ZqiJ1ugMTy1uWqcWb3iaaqpnqrCqWQKadcBRQZy66a9n1lrmiuHBuowieL157EpevIErpLT/KvoGCtopk4+u8JHngKtYNnAAepEES+i4HQ7bKLPRuHptutAuIWun0j4q1zPpajteA76y4ECULREwwBWgNFbuWQSXdy4LA6SIiBr5tcPfcTBAhcUuDuincIGIOElfiQzMQY2+oCzsUsS+lAhVGxBnNQ6v/EQIFSIYb/IsxwVGa6ozN/YryzRmqKBUv1XWgOVOAhiECxIQhyy0Vm0l6cQlT7s4zgBHCPFKXgvv044Cvbjxjm0GI2ywqJrFoc9p/WSxiSIw1NXUGl6fPQcDjkQhDDFqYG2IHKe16AIeQVjN9iK4QmKaaH1zFIRl7TwqL0R+uIF1joI0YNgNfGnjGxJn/2eBOQ7YriAbKcqR0sChOuzhUW2Kw/uR4zBgMUvs5Y5N9tisW5cFyezIGiYSGe2VB+xFhbNOOUoxpQ4fuy/xG2i955HPTO2Jrju4jFf9TqSQL1M996Aov98YJLD3DXg0R0+8W+sMJDATQWVXlFDGW7FN+Ni/LtqYMPRENqgAqJnbnU0aXtJC2N5QnSuF5hAFpAPp7IK3LDyndWnw22AIUZPOjYkN+mjNZArBr8RdcHFRoESlvKcM3oRQC6r4xGQSs5zNbZCEn1sNqFI2uroAZ4fLieBcVFMDvpVwf/y6w78CJsAALlFQ5JEZw1wFsUCE6wwA6pkwoBgfr+QDTAaA0v8Qs5Yxa7VAgzvYxRQVlIcX5YAfc1nYPwqBnkU8DmfMSFKF3uWyW3nlBViimH7Uh8aeLS1BBnEaVKCGpERu8ShQSIAU4bg/NWoEXOET4O3EFqhJNtF2dixTtixFhBfQqZMHMyVEMsmqkKFyXCosTygfxUdfOeBQrdzMLd+Uy12y6ZW8/GUvgbkoYRITWKksJjLNpEpPdiiWyWSmh8jSMlbCrxmcdNM1w/CGW9kLgMt0JSi/qRlZZfOZlDrmFixWjTAmrD/c4oIznUXN8lyznPLM23hCUixtzlNS5tTCMuO5yX7+E02fdE4NZKOFT+QLnpmyZ1nqSdAvvIFemtmnqgr/WrDxQGyRB0kSDv4TICI1ghpLUk2XBNGxnxVIR3OkpAH28cUzlOhl9vmnL5dwgy1cYmsJu5FH23MgTXjiRohwUE1zADMY3IgAR1GAH12mVPvItGlxbMGNEoAymP7jaFJr2PRuZBDi7INHJhnkGEkgH2X9gyPUoKM/NVo2s5wtFKuggd0wMYVc7OA9bSGMALxDhXxMpTVZQABxyCmDxlgtEmgwZ06zVrtq7q+uo7trUwKBBsL9gwhGWAPidPPBvspgNTt1LBVZidir+qISggvNatVHOrnY4SOCowSGZEELfXZOcaZIYC7YGle55o543kBKUeYBj09sEydCOAfyMmOx/wf2R7FvEUgh3vLMyGKDnUtgbsg8ctye0Okr0svedd+nguxRth7uy25qR9Cz+JaxWRiZbxzzQT/ugOqMZnwKy3iLPSZtbroTfYZc51qWAl7WObEALHjhtwvseEdbDpmNWkZIms42xhGfgexB3TDBltQowkTMjyAuOQk68O9di03oY9YSR/DKEL4wcEKG6QsL+xIgx/mlDw9RU8Mn+GGB0tnFAw8YPxezYJTkEeevbmcPpUyNHSD131JGSg8Jj0MJXtQLH7EAJfUcB6kQsjGI0cm7deQhtwKrBmtFMOWgEi9wNqouTc98j/u1F0E0gc0Hy8wPHVurhmP+cZWXFIsh2/+FH3mYEgLQqqLmaCPMp0wwlPO5rgSjKsSWchen75TpUo3aLBgNtbA8ncJuojqYmG41pyML61jTetYalbWtb11rZUB0Taduxq/ttCKBilrVvOz1pZBdplKPylH2VEEJJLFph+74L9NmBkZBXRFWZ/C7zK6Isf2kbUHVSdkR9dW4z3PgLcc53MV09oGhbaFrL1Q8wV5GtrlNnmF/e5gIZlS6x2Nusgz8GL0uOJlevQwCTMyhs6ha8JLqnI7pTNJRFNkYO8qEIBD1eeOI+Dq1ciWpHqdCTtXQU19wE6WsRmh+Xoq3gbYAuqXBlnLCdYiWGgOnJml2hFRpl1hKA5Hz9Eb/KYCjWru0AKiErmaOJTk2wgemPEdJ6DVQmUy7+NYmNXyoXbNqDHKbjqbJ1MwJsGnJEk7c87yNp08yuWel/Ty8DXbHc8Pg3TWhyBjxvckbBF0hAJ8lIexGv9qrguxApzl+JxQHKknuzd0dotAm4AXPYcVOsCZYvsoOIVvwHAnp9tuh2LxxnTVt6JTQAqie3gcNQHzAOPu7UqCQgphFw2MbklgBiB08sfUVYz77B0yAW+G8Rnf/FHMAIiwlvUvQikY+oYYB95h903vBJco7preo4XzZfS9tmrvlmzQEHe7jfmikr1kC4GZPOEfTXJ7kK6AeZwDjgz5D5gFq1lFfSFzx/woihMM7xID34YpDEKD76MV5zd6FLQH9GYD2XRCe9Z4Ewpl1BcT7aJcY7JrBBcECuZnyKQhTdFhoVJjADAOSmcYBJRmDjUACwJUIxN0g1JgH0SAUiN+P6YUMyWD6jUEIaUK14Mn7lcEOaJivVJDtmWBmeFAJEVFplBCBEZ9lmEBh4FCzPM9llFYYZUYCvYLp2d5hqQYD+NizHBUleJCGvULwOQaaqZ2uLdw4BAEICswL4AHInR0FkRfQWJx2aJE9HMWAiMvzlQjItceF/BFC4CDNZAYijlUPlggfOACLCaHkoYkbXZWTgItUfdkYKMSFNNR3EZIWYYWYPAGBGEieWf8PrBBINaRi/ilEGp0IYW0dJ0BFnYnLoZkdFQ1aoM2Un+Hhh7lhQfWbmzyWwghXsCAcLqnZROjbWGgCMgLKLSRfMhGjpljjmTyIRSXA3oxLdURjmwwhQDmjN2mI8b1hrqVZNKVjq2Hjp7GjOv4bPIaaO6YQoNwbk0GEMsajLklTrwRLwKlJQK6SQHLgnuwCRO1ju3GBYuGUqs3RsdxKILyTZhCbMljkQOaKPGSkupFBQxbf2v0JPm6OPq7bQm6Xu9WS24kAKMpSmnCkuZBjR/KTPKKjWZzcUqScnwXNx8UR0YBdeHUdx33d/4TdZ5BdT5gd2lHjEuEaEnpboLGPxBz/BFj9X5cggBK4QtQwktXEz9JRg+qhDcjoTBWESVLpwAngQH2M2GBcjCQ13Mf4DJ3VTBbpQNr13MYVB1HelFECGlLah1JOVdrVY/eQh2g93MYpnqEt1rH8nnPcnmb53u5RIAs4JocJH2rlEndVw2SZmBu8TW1t3nqNkunIRVd+g3T4B+WMARDMBmY+QLVs3hZozhPSjWit14bBj91IkGTkAitdHg3gnmT+A2Xq3lWtYWMBAhOF5DgFAXidD/r9gwZKA545IFJEIHVaIO+JCH5doI20ISrhWu5BZbv9Dn9RUnvEwEgAhRBkhXD831d81/j8xBg4X4EcCv5dQzbojxzm/4H9LQX5LFlCRJdEPCB2dud2Alp20hcBYmAbEubNCJxzjsEQWCEPchgUkGHIPKUkiKGG5oAZkqEavhgbBmN4etqEvIAkkhhLeOaWGRkhmCDa0IvpWIbIgMV4pkI8DMMnXOhxQFLNsVVezdATGlBHSOUL+RBfKKFEcOiKjSEaxlfE8FyU3hg9+CigKZhDSmifNSIh+mQg8eLrZCKJAZ+Y5lkC7GJ69GJgmqgp+VLdXKKbSWR5xiEZeZF7EMJWmlRLyAcw/I8buIyR+MODAOMAnIAw4KlFtYBbjtGRauI6XcKMcJHT3QfXsUyZCsGZ/qKaFgCZ+WKhRkiWgsE5zqMwif/jwpmkpzwAvaFkqZrqL6Hq8cFqlBkkre6SrN5qK0FoHelqrFair2qmrd7jtY1khzxIiDDLqqhPvRQbMy4DN+2JQp5kM5WasV4ac1bkOrRqO5HRFhQLtMCkFxhHNy2r9jCZuF5h5D2rMgShtKqqfwAfvDYDfZZFvVqb+w3rWKwXRATbSKYrFxCBGChruZ1rs+YJsCKQTNLTvJLktHrBve6rvXGruehrFyiN27WDzkSIWJWIhFVf/ClL0uGNDnxlloicSIFoboiOskiNWE2czXDRlJ7r1AlmzMCRFm2Ms67jMngVI5UlWFyZSJEM3kwdBbbpUv1lmQmlXnrNL0ZI1On/UZaRJRethsqobPgIDdUmWh/C0cZ0ZW6yKz+GAei5HdUYhRNEwiRUQg9phydm7S8EYCmU3hnZQrUM3jw04Gy1LRa2Q2bSjAvkl3LmXd7t5sIaE88uQxeNgly0poNh1V6pwwNIwwv0Jd8hJ2hd0PPtHuHRYTpoYNw1Vljq1QkIhsBYARZwFt42GerV696mINrUTeoMwOpIpdi66jGwjkPxAfhwzkoEicLorrWohOp0RXzmg0MYDUIEr+3ul6404GfQzAGeKzZgj/XxCjgcrhPdrrEIqFBkS3Il716ES1YMYIJeLkB85/Us6HH25wFEoCw4qAG+g9Hc6zmcF66cT73u/9f0Xa/9/MNIIK5NkgHozSG/fpBk/IgZBYnEjC6T1AgaeBBgeR7DjS4Q6UrgNks6AG4W2hgLqiAQ7WxNKi6QLUe25BVgrZZxDEUHT2lqYelaiOiWeUQwwKBrliisQFhydGLqdhCsyJAK8KiS2kVvlVAIC4QVJiwvOQrGmIEBsw8eKfDvOlci4MoDl8L/XEjK1kh1wIrUZMtLRa/2nOKBfIYWadGkzocI9+OycG22CK2GBMg0HAUEUgiaxleothGOYJmnsqn7FocgMqqeHYtIDSoPp0Z/QMsfGTLX8uGkOpIIAOkyZiujXGu/UizujrCiTCMJQ8QxmpKTldIkD3CisP+C05aJKedaroajOXbyQ3BjE82SCKjkAFlssDalEt9yJ/EqwOmysHKvL/8yJU9Lw1JUMZPnpzwsqSZuMP/qqybKwZkkszKDRcZkvdGkALNxMwMTLytKN2+BMpPkQ1RzmxCbMq/yNkMTKY8Fwx0E0JnIIZdcOUgSmg5NT5rZwLCknZYs0z0t1mocXlZlZf6POhVBXAZBytZH4dDuOAiDzrzzMNRsNk8Em1W0RV80Rme0Rm80R3e0R380SIe0SI/0R9uyNSUNSNCde5VfEtQmHWAuEbQBQjLmd1Su9qRm6K6BElhWirVEcKrNFqwWE1qpL+xVBnteJ0ifSgfuOaezUzv/c3OS2AHgX1vo3x1cb4PaSHRmtRZM7xPAZ0zJ71Vj3wo84D6xr/AEyP3R7zmET8mSrzkgj1dP9FPXNS5z6R4wqR6EEG0k2RrOIAli6HdQocFiAgyTEIo9ZbH4WG2ARXRk4VGHA3GscBAHKeQGxijbtWZ7k2H+MZ7yhALwNRRoUWAeDRLgcxiR8U3/Tx7TxpxVmfNIradyiTCAEZYBCJYtNMbQsZEAXZGw3IHQ9WYPd63+CofW9TcTt3Izs6agR+URd3Ivt3Rfy3SfSnRXN3YbVHZ/ynVvt3cvs52EM3R/N3lnlK+dtrxyQZzy6Z5hd3eXd3V/20dqgVbxKHFEjDS4/zd877e4jYdxsFPXdF9SNpzfCVfEONl0vzd/K/ftoAD2zoB2kBNKPwx4fAQiTIJ+L7iGu8nt3AAC4IYA4MBMz7BUIjioSFV8b7iKd9p4zEBsFNBpj6hUL4FWYd99MyWDr7iOL1t5nM0CaceJPGqTzFHa4vh47ziS13KS/4mCL3kzNzl8Q7mT67KUk3eVT7mvXrl3azmW0yqXZ/eXd/k8hnmKi7mZm8eZc3iarzkykLSbvzmcx7mczzmdZzSb3zme57me7zmf97mf/zmgB7qgDzqhF7qhHzqiJ7qiLzqjN7qjPzqkR7qkTzqlV7qlXzqmZ7qmbzqnd7qnfzqohzoAhQEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Screening for associated conditions (mental retardation, vision/hearing impairments, speech and language delays, oral motor dysfunction, and epilepsy) is recommended. Neuroimaging (MRI preferred to CT) is recommended for further evaluation if the etiology of the child's CP has not been previously determined. In some children, additional metabolic or genetic testing may be indicated.",
"    <div class=\"footnotes\">",
"     CP: cerebral palsy; EEG: electroencephalogram; MRI: magnetic resonance imaging; CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ashwal S, Russman BS, Blasco PA, et al. Practice Parameter: Diagnostic assessment of the child with crerbral palsy: Report of the Quality Standards Subcommittee of the American Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004; 62:851. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24417=[""].join("\n");
var outline_f23_54_24417=null;
var title_f23_54_24418="Normal thromboelastography and parameters";
var content_f23_54_24418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58281%7ESURG%2F60690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58281%7ESURG%2F60690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Normal thromboelastography and parameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal citrated rapid TEG tracing with normal ACT, R time, K time, alpha angle, MA, G, and LY30.",
"    <div class=\"footnotes\">",
"     R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Clotting factor consumption and hypofibrinogenemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG reflecting clotting factor consumption and hypofibrinogenemia. The red line indicates a normal study.",
"    <br>",
"     This study shows a prolonged ACT, R time, and K time, reflecting enzymatic hypocoagulability; markedly low alpha angle, MA, and G, reflecting platelet hypocoagulability and poor fibrin deposition; normal LY30.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24418=[""].join("\n");
var outline_f23_54_24418=null;
var title_f23_54_24419="Patterns of referred abdominal pain";
var content_f23_54_24419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Patterns of referred abdominal pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain from abdominal viscera often (but no always)&nbsp;localizes according to the structure's embryologic origin, with foregut structures (mouth to proximal half of duodenum) presenting with upper abdominal pain, midgut structures (distal half of duodenum to middle of the transverse colon) presenting with periumbilical pain, and hind gut structures (remainder of colon and rectum, pelvic genitourinary organs) presenting with lower abdominal pain. Radiation of pain may provide insight into the diagnosisl. As examples, pain from pancreatitis may radiate to the back while pain from gallbladder disease may radiate to the right shoulder or subscapular region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24419=[""].join("\n");
var outline_f23_54_24419=null;
var title_f23_54_24420="Culdocentesis";
var content_f23_54_24420=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Culdocentesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24420/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24420/contributors\">",
"     Josephine R Fowler, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24420/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24420/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24420/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24420/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/54/24420/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H651993\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culdocentesis is a procedure performed in women in which peritoneal fluid is aspirated from the posterior pelvic cul-de-sac (pouch of Douglas) through the posterior vaginal fornix. There are few indications for this procedure in current practice. Historically, it was used to evaluate women for hematoperitoneum or a pelvic infection. However, this role has largely been replaced by evaluation with pelvic imaging, image-guided aspiration of fluid, and minimally invasive surgery.",
"   </p>",
"   <p>",
"    The culdocentesis procedure is reviewed here. Other approaches to the evaluation of women with suspected pelvic bleeding or infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culdocentesis may be used to evaluate women with pain in the lower",
"    <span class=\"nowrap\">",
"     abdomen/pelvis",
"    </span>",
"    to determine whether intraabdominal fluid is present and, if present, to reveal the nature of the fluid (eg, serous, purulent, bloody). Thus, the procedure can be helpful in evaluating women with a suspected ruptured ovarian cyst, pelvic inflammatory disease, or ruptured ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24420/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound examination has largely replaced culdocentesis because it accurately identifies the presence of",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    fluid, is more comfortable for the patient, and provides additional information about the pelvis, such as whether there is an adnexal mass or intrauterine pregnancy. Findings on ultrasonography are especially useful when interpreted in conjunction with laboratory test results, such as a complete blood count and pregnancy test. However, culdocentesis may be useful when ultrasonography is not readily available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the procedure, a bimanual examination should be performed to ascertain that the posterior cul-de-sac does not contain cysts, masses, or other structures that might contaminate the peritoneal cavity if perforated or that could impede access to free fluid in the posterior cul-de-sac. A fixed retroverted uterus or a bleeding diathesis are additional contraindications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relevant anatomy is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef59177 \" href=\"UTD.htm?41/3/42036\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consent form for culdocentesis should include the purpose of the procedure, explanation of what will happen in understandable terms, risks and complications, alternatives, and possible outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review the patient's history to exclude",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      suggestive of a bleeding disorder",
"     </li>",
"     <li>",
"      Perform a pelvic (bimanual) examination to assess the posterior cul-de-sac and identify possible pathology",
"     </li>",
"     <li>",
"      Obtain written informed consent",
"     </li>",
"     <li>",
"      Ask the patient to walk or sit upright for 10 to 15 minutes to allow abdominopelvic fluid to pool in the posterior cul-de-sac.",
"     </li>",
"     <li>",
"      Organize instruments for the procedure",
"     </li>",
"     <li>",
"      Explain each step of the culdocentesis to the patient so she knows what to expect",
"     </li>",
"     <li>",
"      Inquire about allergies to medications and iodine so these agents can be avoided",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MATERIALS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Speculum &mdash; The medium Graves speculum is preferred. The Pederson speculum may be used for women with a narrow vagina or virginal women (",
"      <a class=\"graphic graphic_picture graphicRef78911 \" href=\"UTD.htm?0/53/849\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gloves",
"     </li>",
"     <li>",
"      Single toothed tenaculum",
"     </li>",
"     <li>",
"      18-gauge needle attached to a 20 mL syringe containing 5 mL of normal saline",
"     </li>",
"     <li>",
"      Sterile swabs or sponges",
"     </li>",
"     <li>",
"      Long handled ringed forceps",
"     </li>",
"     <li>",
"      A suitable antiseptic, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"     </li>",
"     <li>",
"      Specimen containers",
"     </li>",
"     <li>",
"      A local anesthetic (eg, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      gel)",
"     </li>",
"     <li>",
"      Ferris subsulfate (Monsel's solution) to control bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A topical anesthetic applied to the posterior vagina and posterior cervical lip may provide some anesthesia; however, randomized trials have not consistently demonstrated a significant reduction in pain when compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24420/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Paracervical block or no anesthesia are other options. The failure rate of paracervical block can be as high as 18 percent and complications rarely occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24420/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Steps",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place patient in the dorsal lithotomy position with the head of the examining table elevated 60 degrees to allow peritoneal fluid to pool in the posterior cul-de-sac.",
"     </li>",
"     <li>",
"      Insert speculum to visualize cervix.",
"     </li>",
"     <li>",
"      Cleanse vagina and cervix with antiseptic (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Apply 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      gel to the posterior vagina and posterior cervical lip (optional). Needle puncture for anesthesia may be as painful as the procedure itself and may cause bleeding in the posterior cul-de-sac because the vaginal mucosa of the posterior fornix is very vascular.",
"     </li>",
"     <li>",
"      Grasp the posterior lip of the cervix with the tenaculum and lift the cervix slightly to expose the posterior fornix, which is bounded laterally by the uterosacral ligaments.",
"     </li>",
"     <li>",
"      Insert an 18-gauge needle attached to a 20 mL syringe containing 5 mL of normal saline (or air) through the posterior vaginal wall into the posterior cul-de-sac using a rapid, deliberate thrust. The insertion point is in the midline, about 1 to 2 cm below the insertion of the uterosacral ligaments onto the uterus and below where the vaginal mucosa sweeps off the cervix and crosses the posterior cul-de-sac. The needle should not extend more than 3 to 4 cm through the vaginal mucosa and is directed slightly caudad, away from the uterus and toward the sacrum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An 18-gauge needle is suggested to avoid clotting and increase the yield of the sample. The large needle size may slightly increase the risk of vascular puncture; however, puncture is rare in experienced hands.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inject 5 mL of normal saline (or air) to confirm placement and clear tissue from the needle point. Reposition the needle if there is resistance.",
"     </li>",
"     <li>",
"      Aspirate peritoneal fluid, and then remove the needle slowly (",
"      <a class=\"graphic graphic_figure graphicRef59177 \" href=\"UTD.htm?41/3/42036\">",
"       figure 1",
"      </a>",
"      ). If no fluid is obtained, repeat the procedure at a different angle with a new needle. Discontinue the procedure if unsuccessful after two or three attempts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent steps depend upon type of aspirated fluid.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small amount of",
"      <strong>",
"       clear fluid",
"      </strong>",
"      is normal. Copious peritoneal fluid suggests a ruptured fluid filled cyst or ascites.",
"     </li>",
"     <li>",
"      No fluid in the posterior cul-de-sac can also be a normal finding. However, a",
"      <strong>",
"       dry tap",
"      </strong>",
"      is considered unsatisfactory and suggests that the needle tip is obstructed by tissue due to poor positioning, adhesions, or other pathology.",
"     </li>",
"     <li>",
"      Nonclotting blood indicates active intraperitoneal bleeding. Determine the hematocrit: A hematocrit over 15 percent is most consistent with hemorrhage from a ruptured ectopic pregnancy or actively bleeding ruptured corpus luteum while a hematocrit less than 8 percent is more consistent with blood tinged fluid from a ruptured ovarian cyst or pelvic inflammation.",
"     </li>",
"     <li>",
"      Clotting blood suggests blood from a vein or artery may have been aspirated. The most common site of vessel perforation is the uterine vein. Remove the needle, reinsert a new needle, and aspirate again. The 18-gauge needle is suggested to avoid clotting and increase collected sample yield. The slightly larger needle may slightly increase the risk of puncture. However, risks of puncture are rare in experienced hands.",
"     </li>",
"     <li>",
"      The presence of",
"      <strong>",
"       pus",
"      </strong>",
"      indicates an infectious process, possibly as abscess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of a false positive test for nonclotting blood is less than 2 percent. The presence of nonclotting blood, particularly in a hemodynamically unstable patient, indicates a need for stabilization and surgery to identify and treat the source of bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    .) Additional tests may be indicated prior to surgery, as time permits, depending on the individual clinical circumstances. As an example, if the pregnancy test is negative then a nongynecological source of bleeding should be considered. In trauma patients, the possibility of hepatic or splenic rupture should be suspected and a general surgeon consulted.",
"   </p>",
"   <p>",
"    Purulent fluid indicates infection. Pelvic inflammatory disease is the leading gynecological cause, but nongynecological etiologies should also be considered (eg, appendicitis, diverticulitis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aspiration of clear fluid merely indicates that there is no collection of pus or blood in the pelvis. It does not exclude the possibility of an unruptured ectopic pregnancy, ovarian cyst, tubal infection, or other gynecologic or nongynecologic pathology. Further evaluation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications are rare. There is risk of puncturing the anterior division of the internal iliac vessels or the obturator or pudendal nerve. Inadvertent bowel perforation generally does not lead to morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient may resume normal activities after the procedure.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      are recommended to relieve minor pain, if needed.",
"     </li>",
"     <li>",
"      Instruct the patient to notify her health care provider if she has excessive vaginal bleeding (eg, greater than one pad per hour), fever, purulent vaginal discharge, worsening or persistent pelvic pain, myalgia, or nausea and vomiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Culdocentesis is a procedure in which peritoneal fluid is aspirated transvaginally from the posterior cul-de-sac (pouch of Douglas). It may be used to evaluate women with pain in the lower",
"      <span class=\"nowrap\">",
"       abdomen/pelvis",
"      </span>",
"      to determine whether intraabdominal fluid is present and, if present, to reveal the nature of the fluid (eg, serous, purulent, bloody). The procedure aids in diagnosis of ruptured ectopic pregnancy, ruptured ovarian cysts, pelvic inflammatory disease, and other findings associated with fluid in the pelvis. (See",
"      <a class=\"local\" href=\"#H651993\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A bimanual pelvic examination is performed before the procedure to ascertain that the posterior cul-de-sac does not contain structures that might contaminate the peritoneal cavity if perforated or that could impede access to free fluid in the posterior cul-de-sac. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An 18-gauge needle attached to a 20 mL syringe containing 5 mL of normal saline (or air) is inserted through the posterior vaginal wall into the cul-de-sac and then negative pressure is applied. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detection of a small amount of clear fluid is normal. Copious clear fluid suggests a ruptured fluid filled cyst or ascites. No fluid in the posterior cul-de-sac can be a normal finding; however, a dry tap is considered unsatisfactory and suggests that the needle tip is obstructed by tissue due to poor positioning, adhesions, or other pathology. Nonclotting blood indicates active intraperitoneal bleeding. Clotting blood suggests blood from a vein or artery may have been aspirated. Pus indicates an infectious process, possibly as abscess. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Interpretation of findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4963055\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge Dr. Tu Mai Tran, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24420/abstract/1\">",
"      Roberts MR, Jackimczyk K, Marx J, Rosen P. Diagnosis of ruptured ectopic pregnancy with peritoneal lavage. Ann Emerg Med 1982; 11:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24420/abstract/2\">",
"      Romero R, Copel JA, Kadar N, et al. Value of culdocentesis in the diagnosis of ectopic pregnancy. Obstet Gynecol 1985; 65:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24420/abstract/3\">",
"      Chen PC, Sickler GK, Dubinsky TJ, et al. Sonographic detection of echogenic fluid and correlation with culdocentesis in the evaluation of ectopic pregnancy. AJR Am J Roentgenol 1998; 170:1299.",
"     </a>",
"    </li>",
"    <li>",
"     Mathai, M, Sanghvi, H, Guidotti, RJ, et al. Managing Complications in Pregnancy and Childbirth. A guide for midwives and doctors, Culdocentesis and Colpotomy, Section 3, Procedures, WHO International, Department of Reproductive Health and Research, World Health Organization, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24420/abstract/5\">",
"      Zullo F, Pellicano M, Stigliano CM, et al. Topical anesthesia for office hysteroscopy. A prospective, randomized study comparing two modalities. J Reprod Med 1999; 44:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24420/abstract/6\">",
"      Prefontaine M, Fung-Kee-Fung M, Moher D. Comparison of topical Xylocaine with placebo as a local anesthetic in colposcopic biopsies. Can J Surg 1991; 34:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24420/abstract/7\">",
"      PITKIN RM, GODDARD WB. Paracervical and uterosacral block in obstetrics--a controlled, double-blind study. Obstet Gynecol 1963; 21:737.",
"     </a>",
"    </li>",
"    <li>",
"     Gaufberg, SV. Abortion, complications. E-medicine, www.emedicine.com/emerg/topic4.htm. (Accessed 3/7/05).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3258 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24420=[""].join("\n");
var outline_f23_54_24420=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651993\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MATERIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Steps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INTERPRETATION OF FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4963055\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3258|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/3/42036\" title=\"figure 1\">",
"      Culdocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3258|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/53/849\" title=\"picture 1\">",
"      Speculum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_54_24421="Pelvimetry 2";
var content_f23_54_24421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Pelvic inlet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three anteroposterior diameters of the pelvic inlet are illustrated: the true conjugate, the obstetrically important obstetric conjugate, the obstetrically important obstetric conjugate, and the clinically measurable diagonal conjugate. The anteroposterior diameter of the mid-pelvis is also shown.",
"    <div class=\"footnotes\">",
"     P: sacral promontory; Sym: symphysis pubis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p. 278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24421=[""].join("\n");
var outline_f23_54_24421=null;
var title_f23_54_24422="Neurologic complications of congenital heart disease in adults";
var content_f23_54_24422=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of congenital heart disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24422/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24422/contributors\">",
"     Joseph K Perloff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24422/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24422/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24422/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24422/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/54/24422/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital heart disease in adults is associated with a number of ischemic and nonischemic neurologic complications which will be reviewed here. Specific congenital cardiac lesions and their complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H15#H15\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Neurological complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1202479\">",
"    <span class=\"h1\">",
"     CEREBRAL EMBOLI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emboli leading to stroke or transient ischemic attack may originate in the systemic venous circulation and cross into the systemic arterial circulation via a right-to-left shunt (paradoxical emboli) through an atrial septal defect (ASD) or patent foramen ovale (PFO) or may arise in systemic arterial circulation (eg, left atrial appendage in patients with atrial fibrillation). These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H2#H2\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Sources of emboli'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with cryptogenic stroke have a PFO, an ASD, or an atrial septal aneurysm (ASA) that can be identified by echocardiography. These structures have been implicated in the pathogenesis of embolic events. However, identification of one or more of these atrial septal abnormalities in a patient with an ischemic event does not prove a causal relationship since other sources or conduits of embolism may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=see_link\">",
"     \"Cryptogenic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTIOUS DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Brain abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between brain abscess and congenital heart disease is well established [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. From necropsy studies, the prevalence has been estimated at 2 percent of patients with cyanotic congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/2\">",
"     2",
"    </a>",
"    ]. An abscess can initially develop in adulthood and should be suspected when a cyanotic patient experiences the following symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\", section on 'Clinical manifestations'",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protracted headache",
"     </li>",
"     <li>",
"      Focal neurologic signs",
"     </li>",
"     <li>",
"      Persistent fever",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures may be caused by an acute abscess or can persist long after healing, or can recur years later because of focal scarring.",
"   </p>",
"   <p>",
"    Etiologies include septic cerebral embolus, contiguous extension of infection from otitis media, mastoiditis, sinusitis, and facial or dental infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Less clear is the pathogenesis of what has been called a \"hematogenous\" brain abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. Two preconditions, often associated with cyanotic congenital heart disease, may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacteremia involving the cerebral circulation",
"     </li>",
"     <li>",
"      A focal zone of cerebral vulnerability (ie, ischemic injury)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A right-to-left shunt permits blood-borne bacteria that are normally filtered by the pulmonary circulation to enter the systemic and therefore the cerebral circulations. An area vulnerable to bacteriologic infection can result from a silent sterile paradoxical cerebral embolus or from a zone of encephalomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of brain abscess, including magnetic resonance imaging, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of a brain abscess almost always requires aspiration using a CT-directed stereotactic technique in conjunction with antibiotic therapy. Resection of the abscess is rarely required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32438?source=see_link\">",
"     \"Treatment and prognosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Septic cerebral aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;A septic or bacterial cerebral aneurysm, often incorrectly referred to as a mycotic aneurysm, usually results from a septic embolus originating at a site of infective endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The infected aneurysm may develop de novo or at a site of pre-existing aneurysm. A patient with infective endocarditis who develops focal neurologic signs or meningitis should undergo cerebral imaging, preferably a CT angiogram. Rupture is associated with a high risk of mortality. Diagnosis and management of septal aneurysms is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEMORRHAGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage can be either intracerebral or subarachnoid. Cerebral aneurysms are associated with a risk of central nervous system hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cerebral and spinal aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coarctation of the aorta is associated with cerebral aneurysm with risk of intracerebral or subarachnoid hemorrhage particularly in the second and third decades of life. Hypertension is not a necessary precondition, since cerebral hemorrhage can occur in normotensive patients long after successful coarctation repair [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/9\">",
"     9",
"    </a>",
"    ]. Hemorrhage can be caused by rupture of a congenital aneurysm of the circle of Willis, or rupture of an aneurysm in other cerebral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case control study found that the frequency of intracranial aneurysms among bicuspid aortic valve patients was significantly higher than in a control population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dilated collateral arteries develop within the spinal canal in coarctation. These dilated arteries can compress the spinal cord or can rupture. Arterial rupture causes the clinical picture of subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Every patient with coarctation should have at least one cardiovascular magnetic resonance imaging or computed tomography scan for complete evaluation of the intracranial vessels as well as the thoracic aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Magnetic resonance imaging/computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definitive treatment for intracranial aneurysm is direct clipping, which obliterates blood flow into the aneurysm and preserves the parent artery. Percutaneous coil embolization is another option in select patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antithrombotic therapy in patients at risk for thromboembolism is discussed separately. Risk factors for thromboembolism include atrial fibrillation and history of prior transient ischemic attack or stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=see_link\">",
"     \"Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H9#H9\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cyanotic congenital heart disease, the risk of stroke due to cerebral arterial thrombosis is generally low [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/15\">",
"     15",
"    </a>",
"    ]. Anticoagulants reinforce the intrinsic hemostatic abnormalities in cyanotic patients and increase the risk of intracranial hemorrhage. Therefore, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend routine anticoagulation for patients with cyanotic heart disease, and reserve anticoagulation for only those with specific indications as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H9#H9\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope, defined as a transient loss of consciousness, results from a reduction in cerebral blood flow and oxygen supply to the brain. In patients with congenital heart disease, syncope can be caused by aortic stenosis or hypotension from arrhythmias associated with the congenital abnormality or surgical repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    .) Patients with congenital cardiac disorders may also experience vagal mediated syncope.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In congenital aortic stenosis, syncope is primarily due to an exaggerated exercise-induced fall in systemic vascular resistance mediated by left ventricular baroreceptors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/16\">",
"       16",
"      </a>",
"      ]. Malignant ventricular arrhythmias can be primary or can occur secondary to myocardial ischemia resulting from hypotension or coronary artery disease. In older patients with syncope associated with calcific aortic stenosis, ventricular tachyarrhythmias are probably the chief causes of death.",
"     </li>",
"     <li>",
"      Accessory pathways in pre-excitation syndromes (Wolff-Parkinson-White) permit rapid ventricular response to atrial flutter or fibrillation which can cause weakness, lightheadedness or syncope. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"      </a>",
"      .) The most common congenital abnormality associated with pre-excitation is Ebstein's anomaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"       \"Ebstein's anomaly of the tricuspid valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete atrioventricular block or third degree heart block can cause syncope. Complete heart block can be an isolated congenital abnormality in infants of mothers with",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       anti-La/SSB",
"      </span>",
"      antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"       \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"      </a>",
"      .) Complete heart block can also be associated with specific congenital heart diseases, such as congenitally corrected transposition of the great arteries, or can be a sequel of surgical repair of a congenital malformation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"       \"Congenital third degree (complete) atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SEIZURE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Care should be taken to distinguish a seizure from syncope. One distinguishing feature is that patients with seizures rarely have a rapid recovery. Antecedent faintness or lightheadedness is uncommon prior to a seizure. Other features that distinguish syncope from seizures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seizures can be either primary or secondary to cerebral hypoxia that occurs with hypotension, tachyarrhythmias, or high degree heart block. Primary seizures generally occur in patients with focal organic cerebral lesions, such as a fresh or healed brain abscess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NEUROLOGIC SEQUELAE OF CARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technical refinements of cardiac surgery have reduced the risk of overt neurologic sequelae in individuals with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/5,17-22\">",
"     5,17-22",
"    </a>",
"    ]. Postoperative neuro-imaging identified a significant incidence of hypoxic-ischemic encephalopathy, cerebral atrophy, and subdural hematoma in children with symptoms including alterations of consciousness, localized neurologic deficits, choreoathetoid movements, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/23\">",
"     23",
"    </a>",
"    ]. The long-term effects of these disorders are not well defined.",
"   </p>",
"   <p>",
"    Vocal cord palsy caused by endotracheal intubation is usually self-limiting and resolves in a matter of weeks with only an occasional exception [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients requiring operations for recoarctation are at increased risk for recurrent laryngeal nerve injury. Phrenic nerve palsy with diaphragmatic paralysis is suspected when there is inability to wean from the respirator after open heart surgery. [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/24\">",
"     24",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Spinal cord ischemic injury is a particular concern during repair of coarctation of the aorta or repair of descending aortic aneurysm or dissection and is the result of inadequate collateral circulation. Somatosensory evoked potentials are now monitored routinely during these operations, especially when the adequacy of collateral circulation is in question [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24422/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of coarctation of the aorta\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18026382\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic disorders in patients with congenital heart disease include transient ischemic attack, stroke, brain abscess, cerebral aneurysm (septic and bland), syncope, seizure disorders, and post-operative neurological sequelae. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emboli leading to stroke or transient ischemic attack may originate in the systemic venous circulation and cross into the systemic arterial circulation via a right-to-left shunt (paradoxical emboli) through an atrial septal defect (ASD) or patent foramen ovale (PFO) or may arise in systemic arterial circulation (eg, left atrial appendage in patients with atrial fibrillation). (See",
"      <a class=\"local\" href=\"#H1202479\">",
"       'Cerebral emboli'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of brain abscess in patients with congenital heart disease include septic embolus or contiguous extension of infection from otitis media, mastoiditis, sinusitis, facial, or dental infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Brain abscess'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coarctation of the aorta is associated with cerebral aneurysm with risk of intracerebral or subarachnoid hemorrhage, particularly in the second and third decades of life. Every patient with coarctation should have at least one cardiovascular magnetic resonance imaging or computed tomography scan for complete evaluation of the intracranial vessels as well as the thoracic aorta. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cerebral and spinal aneurysm'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Magnetic resonance imaging/computed tomography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with congenital heart disease, syncope can be caused by aortic stenosis or hypotension from arrhythmias associated with the congenital abnormality or surgical repair. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Syncope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Care should be taken to distinguish a seizure from syncope. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Seizure disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Perloff JK, Child JS, Aboulhosn J. Congenital heart disease in adults, 3, WB Saunders, Philadelphia 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/2\">",
"      Fischbein CA, Rosenthal A, Fischer EG, et al. Risk factors of brain abscess in patients with congenital heart disease. Am J Cardiol 1974; 34:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/3\">",
"      Kurlan R, Griggs RC. Cyanotic congenital heart disease with suspected stroke. Should all patients receive antibiotics? Arch Neurol 1983; 40:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/4\">",
"      Perloff JK, Marelli A. Neurological and psychosocial disorders in adults with congenital heart disease. Heart Dis Stroke 1992; 1:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/5\">",
"      Park SC, Neches WH. The neurologic complications of congenital heart disease. Neurol Clin 1993; 11:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/6\">",
"      Shahler RM, Deuchar DC. Hematogenous brain abscess in cyanotic congenital heart disease. Report of three cases, with complete transposition of the great vessels. Am J Med 1972; 52:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/7\">",
"      Yamada M, Miyasaka Y, Takagi H, Yada K. Cerebral bacterial aneurysm and indications for cerebral angiography in infective endocarditis. Neurol Med Chir (Tokyo) 1994; 34:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/8\">",
"      Patel RL, Richards P, Chambers DJ, Venn G. Infective endocarditis complicated by ruptured cerebral mycotic aneurysm. J R Soc Med 1991; 84:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/9\">",
"      Simon AB, Zloto AE. Coarctation of the aorta. Longitudinal assessment of operated patients. Circulation 1974; 50:456.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff JK. Clinical Recognition of Congenital Heart Disease, 6th ed, Saunders/Elsevier, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/11\">",
"      HODES HL, STEINFELD L, BLUMENTHAL S. Congenital cerebral aneurysms and coarctation of the aorta. Arch Pediatr 1959; 76:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/12\">",
"      Schievink WI, Raissi SS, Maya MM, Velebir A. Screening for intracranial aneurysms in patients with bicuspid aortic valve. Neurology 2010; 74:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/13\">",
"      Chadduck WM, Cathey SL, Gearhart AT, et al. Paraplegia caused by coarctation of the aorta and hydrocephalus. Childs Nerv Syst 1986; 2:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/14\">",
"      Banna MM, Rose PG, Pearce GW. Coarctation of the aorta as a cause of spinal subarachnoid hemorrhage. Case report. J Neurosurg 1973; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/15\">",
"      Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 1993; 87:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/16\">",
"      Mark AL, Kioschos JM, Abboud FM, et al. Abnormal vascular responses to exercise in patients with aortic stenosis. J Clin Invest 1973; 52:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/17\">",
"      Boz&oacute;ky B, Bara D, Kert&eacute;sz E. Autopsy study of cerebral complications of congenital heart disease and cardiac surgery. J Neurol 1984; 231:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/18\">",
"      Luciani GB, Viscardi F, Pilati M, et al. Operative risk and outcome of surgery in adults with congenital valve disease. ASAIO J 2008; 54:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/19\">",
"      Andropoulos DB, Stayer SA, Skjonsby BS, et al. Anesthetic and perioperative outcome of teenagers and adults with congenital heart disease. J Cardiothorac Vasc Anesth 2002; 16:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/20\">",
"      Giamberti A, Chessa M, Abella R, et al. Morbidity and mortality risk factors in adults with congenital heart disease undergoing cardiac reoperations. Ann Thorac Surg 2009; 88:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/21\">",
"      Donofrio MT, Massaro AN. Impact of congenital heart disease on brain development and neurodevelopmental outcome. Int J Pediatr 2010; 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/22\">",
"      Mahle WT, Wernovsky G. Long-term developmental outcome of children with complex congenital heart disease. Clin Perinatol 2001; 28:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/23\">",
"      Ferry PC. Neurologic sequelae of open-heart surgery in children. An 'irritating question'. Am J Dis Child 1990; 144:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/24\">",
"      Hamilton JR, Tocewicz K, Elliott MJ, et al. Paralysed diaphragm after cardiac surgery in children: value of plication. Eur J Cardiothorac Surg 1990; 4:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24422/abstract/25\">",
"      Pollock JC, Jamieson MP, McWilliam R. Somatosensory evoked potentials in the detection of spinal cord ischemia in aortic coarctation repair. Ann Thorac Surg 1986; 41:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1419 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-2A3F076F4F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24422=[""].join("\n");
var outline_f23_54_24422=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18026382\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1202479\">",
"      CEREBRAL EMBOLI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTIOUS DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Brain abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Septic cerebral aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEMORRHAGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cerebral and spinal aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SEIZURE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NEUROLOGIC SEQUELAE OF CARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18026382\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40105?source=related_link\">",
"      Cryptogenic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=related_link\">",
"      Management of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32438?source=related_link\">",
"      Treatment and prognosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14328?source=related_link\">",
"      Treatment of atrial septal abnormalities (PFO, ASD, and ASA) for prevention of stroke in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_54_24423="Leucovorin: Drug information";
var content_f23_54_24423=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Leucovorin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/48/9988?source=see_link\">",
"    see \"Leucovorin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"    see \"Leucovorin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lederle Leucovorin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Chemotherapy Modulating Agent;",
"     </li>",
"     <li>",
"      Rescue Agent (Chemotherapy);",
"     </li>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of weak folic acid antagonist overdosage (eg, trimethoprim, pyrimethamine):",
"     </b>",
"     Oral: 5-15 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Folate-deficient megaloblastic anemia:",
"     </b>",
"     I.M.: &le;1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      High-dose methotrexate-rescue dose:",
"     </b>",
"     Initial: Oral, I.M., I.V.: 15 mg (~10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ); start 24 hours after beginning methotrexate infusion; continue every 6 hours for 10 doses, until methotrexate level is &lt;0.05 micromole/L. Adjust dose as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Normal methotrexate elimination:",
"     </i>",
"     Oral, I.M., I.V.: 15 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Delayed early methotrexate elimination:",
"     </i>",
"     I.V.: 150 mg every 3 hours until methotrexate level is &lt;1 micromole/L, then 15 mg every 3 hours until methotrexate level is &lt;0.05 micromole/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer",
"     </b>",
"     (also refer to Combination Regimens):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over at least 3 minutes (used in combination with fluorouracil 370 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (used in combination with fluorouracil 425 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Methotrexate overdose:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The amount of leucovorin administered should equal the amount of methotrexate inadvertently administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: 1 mg per mg of methotrexate inadvertently administered; 100-1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3-6 hours has been used; administer until methotrexate levels decrease to goal level or longer if methotrexate levels are unavailable or if patient has renal dysfunction or third-space storage (ascites, pleural effusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     A nomogram for leucovorin rescue in cancer patients receiving high-dose methotrexate based upon a 48-hour methotrexate level may be helpful (Widemann, 2006). Methotrexate level:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;80 micromole/L: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;8 to &lt;80 micromole/L: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;2 to &lt;8 micromole/L: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &ge;0.1 to &lt;2 micromole/L: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Use of I.T. leucovorin is not advised (Jardine, 1996; Smith, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pemetrexed toxicity (unlabeled dose):",
"     </b>",
"     I.V.: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once, followed by 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 hours for 8 days (used in clinical trial for CTC grade 4 leukopenia &ge;3 days; CTC grade 4 neutropenia &ge;3 days; immediately for CTC grade 4 thrombocytopenia, bleeding associated with grade 3 thrombocytopenia, or grade 3 or 4 mucositis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Cofactor therapy in methanol toxicity (unlabeled use):",
"     </b>",
"     I.V.: 1 mg/kg (maximum dose: 50 mg) over 30-60 minutes every 4-6 hours.  Therapy should continue until methanol and formic acid have been completely eliminated (Barceloux, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of pyrimethamine hematologic toxicity in HIV-positive patients (unlabeled uses; CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isosporiasis (",
"     <i>",
"      Isospora belli",
"     </i>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 10-25 mg once daily (in combination with pyrimethamine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chronic maintenance (secondary prophylaxis): 5-10 mg once daily (in combination with pyrimethamine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP): Prophylaxis (primary and secondary): 25 mg once weekly (in combination with pyrimethamine [with dapsone])",
"     <b>",
"      or",
"     </b>",
"     10 mg once daily (in combination with pyrimethamine [with atovaquone])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxoplasmosis (",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary prophylaxis: 25 mg once weekly (in combination with pyrimethamine [with dapsone])",
"     <b>",
"      or",
"     </b>",
"     10 mg once daily (in combination with pyrimethamine [with atovaquone])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 10-25 mg once daily (in combination with pyrimethamine [with either sulfadiazine, clindamycin, atovaquone, or azithromycin]).",
"     <b>",
"      Note:",
"     </b>",
"     May increase leucovorin to 50-100 mg/day in divided doses in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chronic maintenance (secondary prophylaxis): 10-25 mg once daily (in combination with pyrimethamine [with either sulfadiazine or clindamycin])",
"     <b>",
"      or",
"     </b>",
"     10 mg once daily (in combination with pyrimethamine [with atovaquone])",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F187385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"      see \"Leucovorin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of weak folic acid antagonist overdosage (eg, trimethoprim, pyrimethamine):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Folate-deficient megaloblastic anemia:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      High-dose methotrexate-rescue dose:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Cofactor therapy in methanol toxicity (unlabeled use):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of pyrimethamine hematologic toxicity in HIV-positive patients (unlabeled uses; CDC, 2009):",
"     </b>",
"     Infants and Children &gt;1 month of age:",
"     <b>",
"      Note:",
"     </b>",
"     Leucovorin should continue for 1 week after pyrimethamine is discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Toxoplasmosis (",
"     <i>",
"      Toxoplasma gondii",
"     </i>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary prophylaxis: Oral: 5 mg once every 3 days (in combination with pyrimethamine [with either dapsone or  atovaquone])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Secondary prophylaxis: Oral: 5 mg once every 3 days (in combination with pyrimethamine [with either sulfadiazine, atovaquone, or clindamycin])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment (congenital): Oral or I.M.: 10 mg with every pyrimethamine dose (in combination with either sulfadiazine or clindamycin); treatment duration: 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment (acquired): Oral: Acute induction: 10-25 mg once daily (in combination with pyrimethamine [with either sulfadiazine, clindamycin, or atovaquone]) for &ge;6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [strength expressed as base]: 50 mg, 100 mg, 200 mg, 350 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [strength expressed as base, preservative free]: 10 mg/mL (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [strength expressed as base]: 5 mg, 10 mg, 15 mg, 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F187347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to calcium content, do not administer I.V. solutions at a rate &gt;160 mg/minute; not intended for intrathecal use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Refer to individual protocols. Should be administered I.M., I.V. push, or I.V. infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Toxicity to normal tissues may be irreversible if leucovorin is not initiated by ~40 hours after the start of methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     As a rescue after folate antagonists: Administer by I.V. bolus, I.M., or orally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Do not administer orally in the presence of nausea or vomiting. Doses &gt;25 mg should be administered parenterally.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In combination with fluorouracil: Fluorouracil activity, the fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion. Other administration schedules have been used; refer to individual protocols.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F187408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      10",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, sterile water for injection, bacteriostatic water, bacteriostatic NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, anidulafungin, aztreonam, bleomycin, cefepime, cisplatin, cladribine, cyclophosphamide, docetaxel, doxorubicin, doxorubicin liposome, etoposide phosphate, filgrastim, fluconazole, fluorouracil, furosemide, gemcitabine, granisetron, heparin, irinotecan, linezolid, methotrexate, metoclopramide, mitomycin, oxaliplatin, pemetrexed, piperacillin/tazobactam, tacrolimus, teniposide, thiotepa, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, droperidol, foscarnet, sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, doxorubicin, fluorouracil, furosemide, heparin, methotrexate, metoclopramide, mitomycin, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone, Ddroperidol.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote for folic acid antagonists (methotrexate, trimethoprim, pyrimethamine) and rescue therapy following high-dose methotrexate; in combination with fluorouracil in the treatment of colon cancer; treatment of megaloblastic anemias when folate is deficient as in infancy, sprue, pregnancy, and nutritional deficiency when oral folate therapy is not possible",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10068593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive cofactor therapy in methanol toxicity; prevention of pyrimethamine hematologic toxicity in HIV-positive patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Leucovorin may be confused with Leukeran&reg;, Leukine&reg;, LEVOleucovorin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Folinic acid may be confused with folic acid",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Folinic acid is an error prone synonym and should not be used",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Toxicities (especially gastrointestinal toxicity) of fluorouracil is higher when used in combination with leucovorin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, pruritus, erythema, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pernicious anemia or vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     -deficient megaloblastic anemias",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5524355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluorouracil: Leucovorin may increase the toxicity of 5-fluorouracil; dose of 5-fluorouracil may need decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfamethoxazole-trimethoprim: Combination of leucovorin and sulfamethoxazole-trimethoprim for the acute treatment  of PCP in patients with HIV infection has been reported to cause increased rates of treatment failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Powder for injection: When doses &gt;10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     are required, reconstitute using sterile water for injection, not a solution containing benzyl alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection: Due to calcium content, do not administer I.V. solutions at a rate &gt;160 mg/minute. Not intended for intrathecal use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings and precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Methotrexate overdose: When used for the treatment of a methotrexate overdose, administer as soon as possible. Do not wait for the results of a methotrexate level before initiating therapy. It is important to adjust the leucovorin dose once a methotrexate level is known. The dose may need to be increased or administration prolonged in situations in which methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration).",
"     <b>",
"      Never administer leucovorin intrathecally.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Methotrexate rescue therapy: Methotrexate serum concentrations should be monitored to determine dose and duration of leucovorin therapy. Dose may need increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration).",
"     <b>",
"      Never administer leucovorin intrathecally.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Capecitabine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim.  Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5524281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F187374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5527100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended in breast-feeding women. Refer to Folic Acid monograph.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5524286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solutions for injection contain calcium 0.004 mEq per leucovorin 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Leucovorin Calcium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (50 mL): $27.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Leucovorin Calcium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $5.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (1): $19.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     350 mg (1): $22.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $48.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Leucovorin Calcium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (50): $140.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (12): $90.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (24): $254.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (25): $600.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F187342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     High-dose methotrexate therapy: Plasma methotrexate concentration; leucovorin is continued until the plasma methotrexate level &lt;0.05 micromole/L. With 4- to 6-hour high-dose methotrexate infusions, plasma drug values in excess of 50 and 1 micromole/L at 24 and 48 hours after starting the infusion, respectively, are often predictive of delayed methotrexate clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil therapy: CBC with differential and platelets, liver function tests, electrolytes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acido Folinico/Leucovorina (CN);",
"     </li>",
"     <li>",
"      Antrex (FI, PL, TW);",
"     </li>",
"     <li>",
"      Asovorin (AR);",
"     </li>",
"     <li>",
"      Cafona (TW);",
"     </li>",
"     <li>",
"      Cafonate (PH);",
"     </li>",
"     <li>",
"      Calcium Folinate (NZ);",
"     </li>",
"     <li>",
"      Calciumfolinat Faulding (SE);",
"     </li>",
"     <li>",
"      Calciumfolinat Pharmalink (SE);",
"     </li>",
"     <li>",
"      Calciumfolinat &rdquo;Faulding&rdquo; (DK);",
"     </li>",
"     <li>",
"      Calciumfolinat-Ebewe (PL, TW);",
"     </li>",
"     <li>",
"      Calfonat (DK);",
"     </li>",
"     <li>",
"      Dalisol (MX);",
"     </li>",
"     <li>",
"      Estroquin (PE);",
"     </li>",
"     <li>",
"      Ferbon (KP);",
"     </li>",
"     <li>",
"      Folcasin (ID);",
"     </li>",
"     <li>",
"      Folical (CO);",
"     </li>",
"     <li>",
"      Folina 15 (TW);",
"     </li>",
"     <li>",
"      Folinato de Calcio Dakota Farma (PT);",
"     </li>",
"     <li>",
"      Kalcij-folinat (HR);",
"     </li>",
"     <li>",
"      Lederfolin (ES, IE, IT);",
"     </li>",
"     <li>",
"      Lederfoline (FR, PT);",
"     </li>",
"     <li>",
"      Ledervorin Calcium (BE, LU, NL);",
"     </li>",
"     <li>",
"      Leucocalcin (PY);",
"     </li>",
"     <li>",
"      Leuconolver (VE);",
"     </li>",
"     <li>",
"      Leucovorin (AT, BG, CH, DE, GR, IE, IL, PL, TH, UY);",
"     </li>",
"     <li>",
"      Leucovorin Ca (PL);",
"     </li>",
"     <li>",
"      Leucovorin Calcium (AU, CZ, HK, HN, ID, IN, MY, NZ, TH);",
"     </li>",
"     <li>",
"      Leucovorine Abic (NL);",
"     </li>",
"     <li>",
"      Lifacor (PH);",
"     </li>",
"     <li>",
"      Likelin (CL);",
"     </li>",
"     <li>",
"      Lovorin (PH);",
"     </li>",
"     <li>",
"      Medifolin (PT);",
"     </li>",
"     <li>",
"      Medsavorina (MX);",
"     </li>",
"     <li>",
"      Nyrin (SG);",
"     </li>",
"     <li>",
"      Refolinon (GB, LU);",
"     </li>",
"     <li>",
"      Rescufolin (NO);",
"     </li>",
"     <li>",
"      Rescuvolin (BE, CH, DK, GR, KP, LU, PH, SE, TH, TW);",
"     </li>",
"     <li>",
"      Robin (KP);",
"     </li>",
"     <li>",
"      Rontafur (AR);",
"     </li>",
"     <li>",
"      Tecnovorin (BR, EC);",
"     </li>",
"     <li>",
"      Vorina (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A reduced form of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate. Leucovorin actively competes with methotrexate for transport sites, displaces methotrexate from intracellular binding sites, and restores active folate stores required for DNA/RNA synthesis. Stabilizes the binding of 5-dUMP and thymidylate synthetase, enhancing the activity of fluorouracil. When administered with pyrimethamine for the treatment of opportunistic infections, leucovorin reduces the risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Methanol toxicity treatment: Formic acid (methanol&rsquo;s toxic metabolite) is normally metabolized to carbon dioxide and water by 10-formyltetrahydrofolate dehydrogenase after being bound to tetrahydrofolate. Administering a source of tetrahydrofolate may aid the body in eliminating formic acid.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, I.M.: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Intestinal mucosa and hepatically to 5-methyl-tetrahydrofolate (5MTHF; active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Saturable at oral doses &gt;25 mg; 25 mg (97%), 50 mg (75%), 100 mg (37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: ~2 hours; I.V.: Total folates: 10 minutes; 5MTHF: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barceloux DG, Bond GR, Krenzelok EP, et al, &ldquo;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2002, 40(4):415-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/12216995/pubmed\" id=\"12216995\" target=\"_blank\">",
"        12216995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleyer WA, &ldquo;New Vistas for Leucovorin in Cancer Chemotherapy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1989, 63(6 Suppl):995-1007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flombaum CD and Meyers PA. &ldquo;High-Dose Leucovorin as Sole Therapy for Methotrexate Toxicity,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(5):1589-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/10334548/pubmed\" id=\"10334548\" target=\"_blank\">",
"        10334548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grogan L, Sotos GA, and Allegra CJ, &ldquo;Leucovorin Modulation of Fluorouracil,&rdquo;",
"      <i>",
"       Oncology (Huntingt)",
"      </i>",
"      , 1993, 7(8):63-72.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hansen RM, &ldquo;Systemic Therapy in Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1990, 150(11):2265-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/2241436/pubmed\" id=\"2241436\" target=\"_blank\">",
"        2241436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobsen D and McMartin KE, &ldquo;Methanol and Ethylene Glycol Poisonings. Mechanism of Toxicity, Clinical Course, Diagnosis and Treatment,&rdquo;",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(5):309-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/3537623/pubmed\" id=\"3537623\" target=\"_blank\">",
"        3537623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jardine LF, Ingram LC, and Bleyer WA, &ldquo;Intrathecal Leucovorin After Intrathecal Methotrexate Overdose,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 1996, 18(3):302-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/8689347/pubmed\" id=\"8689347\" target=\"_blank\">",
"        8689347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jolivet J, &ldquo;Role of Leucovorin Dosing and Administration Schedule,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1995, 31A(7-8):1311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Machover D, &ldquo;A Comprehensive Review of 5-Fluorouracil and Leucovorin in Patients With Metastatic Colorectal Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1997, 80(7):1179-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/9317168/pubmed\" id=\"9317168\" target=\"_blank\">",
"        9317168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGuire BW, Sia LL, Leese PT, et al, &ldquo;Pharmacokinetics of Leucovorin Calcium After Intravenous, Intramuscular, and Oral Administration,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(1):52-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/3257913/pubmed\" id=\"3257913\" target=\"_blank\">",
"        3257913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Colon Cancer,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rustum YM, &ldquo;Modulation of Fluoropyrimidines by Leucovorin: Rationale and Status,&rdquo;",
"      <i>",
"       J Surg Oncol Suppl",
"      </i>",
"      , 1991, 2:116-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/1832538/pubmed\" id=\"1832538\" target=\"_blank\">",
"        1832538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SW and Nelson LS, &ldquo;Case Files of the New York City Poison Control Center: Antidotal Strategies for the Management of Methotrexate Toxicity,&rdquo;",
"      <i>",
"       J Med Toxicol",
"      </i>",
"      , 2008, 4(2):132-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/18570175/pubmed\" id=\"18570175\" target=\"_blank\">",
"        18570175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stover P and Schirch V, &ldquo;The Metabolic Role of Leucovorin,&rdquo;",
"      <i>",
"       Trends Biochem Sci",
"      </i>",
"      , 1993, 18(3):102-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/8480361/pubmed\" id=\"8480361\" target=\"_blank\">",
"        8480361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Martinez JF, and Xu QA, &ldquo;Incompatibility of Fluorouracil With Leucovorin Calcium or Levoleucovorin Calcium,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(7):710-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/7627739/pubmed\" id=\"7627739\" target=\"_blank\">",
"        7627739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Delden C and Hirschel B, \"Folinic Acid Supplements to Pyrimethamine-Sulfadiazine for",
"      <i>",
"       Toxoplasma encephalitis",
"      </i>",
"      Are Associated With Better Outcome,\"",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1996, 173(5):1294-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/8627092/pubmed\" id=\"8627092\" target=\"_blank\">",
"        8627092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Law S, and Puodziunas A, &ldquo;Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers,&rdquo;",
"      <i>",
"       Can J Hosp Pharm",
"      </i>",
"      , 2005, 58(4):212-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widemann BC and Adamson PC, &ldquo;Understanding and Managing Methotrexate Nephrotoxicity,&rdquo;",
"      <i>",
"       Oncologist,",
"      </i>",
"      2006, 11(6):694-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/54/24423/abstract-text/16794248/pubmed\" id=\"16794248\" target=\"_blank\">",
"        16794248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9548 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24423=[""].join("\n");
var outline_f23_54_24423=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508393\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187403\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187366\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187385\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187367\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160285\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160286\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187344\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187331\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187347\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187408\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10068593\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187410\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187401\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187350\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5524355\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299583\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187338\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187340\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5524281\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187374\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527100\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5524286\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524636\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187342\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187352\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187334\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187349\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/48/9988?source=related_link\">",
"      Leucovorin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=related_link\">",
"      Leucovorin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_54_24424="Horner syndrome due to internal carotid artery dissection";
var content_f23_54_24424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Horner syndrome due to internal carotid artery dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Horner syndrome (miosis and ptosis).",
"    <br>",
"     (B) Multiple left frontoparietal acute ischemic lesions on diffusion-weighted MRI.",
"     <br>",
"      (C) Carotid angiography with evidence of left extracranial internal carotid artery occlusion.",
"      <br>",
"       (D) Internal carotid artery mural hematoma due to dissection evident on MRI scan.",
"       <br>",
"        (E) Intimal flap (arrows) appearance on Duplex scan, a pathognomonic sign of dissection.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Mazzucco S, Rizzuto N. Teaching NeuroImage: Horner syndrome due to internal carotid artery dissection. Neurology 2006; 66:E19. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24424=[""].join("\n");
var outline_f23_54_24424=null;
var title_f23_54_24425="Etiology and evaluation of the child with muscle weakness";
var content_f23_54_24425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and evaluation of the child with muscle weakness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24425/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24425/contributors\">",
"     Russell Migita, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24425/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/54/24425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/54/24425/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/54/24425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness is a decreased ability to voluntarily and actively move muscles against resistance. Weakness is easily confused with hypotonia or ataxia. Hypotonia is a decreased resistance to passive range of motion. Ataxia refers to decreased muscular coordination. Weakness may arise from any portion of the motor unit, including the upper motor neuron, lower motor neuron, peripheral nerve, neuromuscular junction, or the muscles. Due to the broad differential diagnosis of weakness and the potential for life-threatening complications, the evaluation of weakness requires a careful and comprehensive approach [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24425/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to the child with muscle weakness will be reviewed here. The approach to an infant or newborn with hypotonia or weakness is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=see_link\">",
"     \"Approach to the infant with hypotonia and weakness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=see_link\">",
"     \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Upper motor neuron weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper motor neuron weakness arises from lesions in the cerebral cortex and corticospinal tracts down to, but not including, the anterior horn cell in the dorsal spinal cord. Although patients with acute upper motor neuron lesions may initially present with decreased spinal cord reflexes accompanied by hypotonia or paralysis on the opposite side of the central nervous system lesion, they ultimately develop spasticity, hyperreflexia, and \"upper motor neuron\" signs (eg, positive Babinski sign).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lower motor neuron weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower motor neuron weakness results from lesions located in the anterior horn cell, peripheral nerve, neuromuscular junction, or muscle. Patients with lower motor neuron weakness typically display muscle weakness, hypotonia, fasciculations, and decreased spinal cord reflexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACUTE MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the conditions that cause acute muscle weakness are potentially life-threatening. Mortality due to acute muscle weakness is typically caused by respiratory failure or by lesions in the brain that cause both weakness and increased intracranial pressure (",
"    <a class=\"graphic graphic_table graphicRef81649 \" href=\"UTD.htm?35/18/36140\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cerebral cortex",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intracranial hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intracranial hemorrhage represents one of the most devastating causes of weakness. Traumatic epidural or subdural hematoma is common in children who have sustained severe head trauma. Rapid recognition and evacuation of an epidural hematoma in children with head trauma is frequently associated with complete recovery. The treatment of a subdural hematoma is less successful in most cases because of extensive brain damage, often secondary to abusive head injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=see_link\">",
"     \"Intracranial subdural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly, rupture of a preexisting arteriovenous malformation or aneurysm may cause subarachnoid hemorrhage. Most of these patients are asymptomatic prior to rupture. These children present with sudden weakness, often associated with altered mental status or severe headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke is a rare cause of weakness in children. Thrombotic stroke may be caused by a hypercoagulable state such as factor V Leiden deficiency, protein C or S deficiency, or sickle cell disease. Embolic strokes are less common and may be considered in children with congenital or acquired heart disease. Acquired or congenital vasculopathy caused by vasculitis, moyamoya disease, or specific metabolic disorders (eg, homocystinuria) comprise additional unusual causes of stroke in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Brain tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial tumors, either malignant or benign, may cause weakness. Intracranial tumors can present with or be exacerbated by hemorrhage into the tumor. These patients usually either have a history of known brain tumor or a history of clumsiness, weakness, behavioral changes, and vomiting. When the acute hemorrhage occurs, symptoms include weakness, severe headache, and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=see_link\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Todd paralysis is a temporary focal weakness following a seizure. It generally improves rapidly during the postictal period with resolution in minutes to hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\", section on 'Behavior after the event'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hemiplegic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical migrainous aura is characterized by progressive neurologic deficits or disturbances with subsequent complete recovery. Visual disturbances are the most common type of aura. However, auras may also involve other senses or occasionally cause motor or speech deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H4#H4\">",
"     \"Classification of migraine in children\", section on 'Migraine with aura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemiplegic migraine is manifested by motor and sensory symptoms that are unilateral. These symptoms can last longer than the headache itself. Complete recovery may take weeks in some cases; permanent weakness can occur after multiple attacks. Hemiplegic migraine is divided into familial and sporadic subtypes. Familial hemiplegic migraine is an uncommon autosomal dominant disorder linked to specific gene mutations. In addition, there are some patients who are the first member of their family to have hemiplegic migraine. They are referred to as having spontaneous hemiplegic migraine and may or may not carry one of the described gene variants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link\">",
"     \"Hemiplegic migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Alternating hemiplegia of childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;This very rare condition is characterized by periodic episodes of hemiplegia or quadriplegia beginning in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24425/abstract/2\">",
"     2",
"    </a>",
"    ]. Other findings include, dystonia, paroxysmal eye movements (eg, nystagmus), seizures, cognitive impairment, and ataxia. Episodes often improve or resolve after sleep. A family history of migraine may also be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Spinal cord",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Spinal cord trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic injuries may damage the spinal cord, either transiently or permanently. Spinal cord concussion may occur after a direct blow to the head, neck, or back and presents with impairment of sensory and motor function below the level of the injury. Patients with this injury generally recover, often within hours. Other traumatic injuries include spinal epidural hematoma, vertebral column fractures or dislocations, and spinal cord injury without radiographic abnormality (SCIWORA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Spinal cord tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal weakness and peripheral or back pain are the most common presenting symptoms of a spinal cord tumor. Incontinence may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=see_link\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Paraspinal infection or inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural abscess and discitis are rare causes of weakness in children. Children with epidural abscess may display the classic diagnostic triad of fever, spinal pain, and neurologic deficits, but only a few patients have all three components at presentation. Over time, an untreated epidural abscess is associated with a typical progression of symptoms from back pain (often focal and severe), to root pain (described as \"shooting\" or \"electric shocks\"), to neurologic deficits (motor weakness, sensory changes, and bowel and bladder dysfunction), and finally paralysis, which may quickly become irreversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidural abscess\", section on 'Spinal epidural abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discitis refers to inflammation of the intervertebral disc. Most patients with discitis are under three years of age and complain of back pain, with or without fever, but rarely, the infection may spread to the epidural space and cause weakness. The etiology is controversial. The current consensus, backed by scant supportive evidence, is that discitis in children usually represents low-grade infection and is on one end of the spectrum of vertebral osteomyelitis. Although disc biopsy is not necessary for diagnosis, when it is performed, as many as 60 percent of tissue samples grow bacteria, usually Staphylococcus aureus. However, children often recover without antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link&amp;anchor=H14#H14\">",
"     \"Back pain in children and adolescents: Overview of causes\", section on 'Discitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Transverse myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelitis is an inflammatory condition of unclear etiology. Symptoms are characterized by motor and sensory deficits attributable to myelin destruction in one or both sides of the spinal cord. They include weakness, paresthesias, and sphincter dysfunction. These typically present over a few days, with paresthesias preceding the weakness and urinary retention. A hyperacute presentation sometimes occurs with rapid onset of paraplegia, sensory abnormalities, and urinary retention. This form is often associated with significant back pain. A discrete sensory level may or may not be detected with either presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders affecting the spinal cord\", section on 'Transverse myelitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link&amp;anchor=H8#H8\">",
"     \"Differential diagnosis of acute central nervous system demyelination in children\", section on 'Transverse myelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anterior horn cell disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Poliomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although polio no longer poses the public health threat in the United States and other developed countries that it once did, areas of endemic wild-type poliovirus still exist in other parts of the world. Poliovirus is a species of human enterovirus. A small fraction of patients with poliovirus infection develop central nervous system (CNS) infection. After invading the CNS, the virus uncoats, viral replication occurs, and the motor neuron dies, leading to paralysis of muscle fibers supplied by this motor neuron. Weakness may vary from one muscle or group of muscles, to quadriplegia, and respiratory failure. Tone is reduced, nearly always in an asymmetric manner. Proximal muscles usually are affected more than distal ones, and legs more commonly than arms. Reflexes are decreased or absent. The sensory examination is normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link&amp;anchor=H3#H3\">",
"     \"Polio and infectious diseases of the anterior horn\", section on 'Poliovirus and poliomyelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Peripheral Nerve",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guillain-Barr&eacute; syndrome (GBS) is an acute inflammatory demyelinating polyradiculopathy believed to be due to an autoimmune response. In children, GBS most commonly presents with an acute, progressive, symmetric, ascending weakness. Less commonly, patients can present with primarily sensory dysfunction or ophthalmoplegia, ataxia and bulbar dysfunction (Miller-Fisher Syndrome). GBS is the most common form of acute flaccid paralysis in the United States. If weakness progresses, respiratory failure requiring mechanical ventilation may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=see_link\">",
"     \"Treatment of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Peripheral nerve toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxins that can cause life-threatening weakness include heavy metals (eg, arsenic, mercury, thallium), ciguatera fish poisoning (ciguatoxin), and paralytic shellfish poisoning (saxitoxin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link&amp;anchor=H17#H17\">",
"     \"Marine toxins\", section on 'Paralytic shellfish poisoning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=see_link&amp;anchor=H48#H48\">",
"     \"Overview of acquired peripheral neuropathies in children\", section on 'Toxins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Acute intermittent porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intermittent porphyria (AIP) is both the most common and most severe of the inherited porphyrias. It is an autosomal dominant disorder resulting from a partial deficiency of porphobilinogen deaminase (PBGD) activity, the third enzyme in the pathway of heme synthesis. The neuropathic symptoms most commonly involve muscle weakness with more involvement of proximal muscle groups. Symptoms generally begin after puberty and may be triggered by stress, decreased food intake, a number of different medications (eg, barbiturates, sulfonamides, estrogen,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/45/33492?source=see_link\">",
"     griseofulvin",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"     table 2",
"    </a>",
"    ), and, in women, menses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other conditions may cause peripheral neuropathy with varying degrees of weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=see_link\">",
"     \"Overview of acquired peripheral neuropathies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuromuscular junction disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases of the neuromuscular junction affect strength, but usually leave sensory function intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Botulism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulism is caused by a neurotoxin that blocks the release of acetylcholine at the neuromuscular junction. The toxin is produced by the Clostridium botulinum bacterium, a soil-dwelling, gram-positive anaerobe. There are three main presentations of botulism: foodborne, wound-associated, and most commonly, infant botulism. Classic, or foodborne botulism, is caused by eating food contaminated by clostridial toxin. Symptoms include vision changes, difficulty swallowing, and, ultimately, progressive weakness. Wound botulism presents similarly to classic botulism but the toxin arises from a grossly infected wound. In infant botulism, the bacteria are ingested and produce toxin within the child's gastrointestinal tract. Infants with botulism present with constipation, lethargy, and poor tone. Honey, which can be contaminated with C botulinum spores, has been associated with infant botulism. Infant botulism, although rare, is one of the most common causes of acute, generalized weakness in infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link&amp;anchor=H14#H14\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Infant botulism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is an antibody-mediated autoimmune disease that affects the postsynaptic neuromuscular junction. Most commonly, it presents in a slowly progressive fashion. However, myasthenic crises can occur, which can lead to respiratory failure. The most common symptoms of myasthenia gravis include ptosis and diplopia. These symptoms are generally exacerbated by activity and relieved by rest. Transient neonatal myasthenia affects 10 to 15 percent of babies born to mothers with myasthenia gravis. It can lead to weakness, dysphagia, and occasionally, respiratory distress or failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Organophosphate or carbamate poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphates and carbamates are potent cholinesterase inhibitors capable of causing severe cholinergic toxicity with weakness and paralysis following cutaneous exposure, inhalation, or ingestion (",
"    <a class=\"graphic graphic_figure graphicRef75227 \" href=\"UTD.htm?36/57/37790\">",
"     figure 1",
"    </a>",
"    ). Although structurally distinct, the clinical manifestations and management of organophosphate and carbamate toxicity are similar. A rapid overview provides clinical features and emergent management of organophosphate and carbamate toxicity (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"UTD.htm?18/23/18813\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"     \"Organophosphate and carbamate poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Neurotoxic snake envenomation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venoms of the elapids of the Australia-Pacific region (Cobra, water snake) are associated with severe neurotoxicity. Neurotoxicity is characterized initially by ptosis, diplopia, and bulbar palsy with onset between 1 to 10 hours following envenomation. Symptoms can later progress to dysarthria and more generalized weakness. As a result, frequent, serial observations for ptosis, diplopia, and impaired swallowing function are of paramount importance. Ventilatory support may be required for airway protection or respiratory paralysis. In the United States, most snake envenomations are not neurotoxic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=see_link\">",
"     \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Tick paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tick paralysis is a rare form of weakness caused by toxin excreted during feeding by female ticks, primarily from the Dermacentor and Ixodes genus.",
"   </p>",
"   <p>",
"    Tick paralysis caused by Dermacentor ticks usually begins with paresthesias and a sense of fatigue and weakness, although individual patients may sometimes appear irritable or restless and complain of muscular pain. Fever is characteristically absent, and there is no change in the sensorium or headache unless severe hypoxia or hypercarbia are present. Most patients eventually develop an unsteady gait that progresses to an ascending complete paralysis. Deep tendon reflexes are characteristically absent. Respiratory paralysis and death can occur in severe cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3494?source=see_link\">",
"     \"Tick paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Muscle",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury can lead to breakdown of skeletal muscle tissue, causing the release of creatinine kinase and other intracellular substances. The classic symptom triad includes myalgias, weakness, and dark urine. Rhabdomyolysis in children most commonly occurs as a result of viral myositis. Other causes include trauma, connective tissue disease, toxins, and exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myositis may occur in the setting of systemic viral or bacterial infection. Viral myositis is a common pediatric condition that is usually self-limited. However, in its most severe and rare form, it can cause severe weakness with rhabdomyolysis. Although many viruses can cause myositis, it is most commonly due to infection with influenza (benign acute childhood myositis) which rarely progresses to rhabdomyolysis. This condition is characterized by refusal to walk with marked tenderness of bilateral calf muscles and pain on passive or active dorsiflexion of the feet in a child who is in the recovery phase of influenza. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=see_link&amp;anchor=H3#H3\">",
"     \"Viral myositis\", section on 'Benign acute childhood myositis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course of acute viral myositis complicated by massive rhabdomyolysis is highly variable, and relates to the course of the complications of rhabdomyolysis, including renal failure, fluid and electrolyte abnormalities, and cardiac arrhythmias. Other complications that can occur include respiratory failure secondary to respiratory muscle necrosis and weakness, infection, and pulmonary embolus. In most cases, with prompt recognition and appropriate directed therapy, muscle strength and renal function recover fully, usually within one to two weeks of the onset of rhabdomyolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=see_link&amp;anchor=H4#H4\">",
"     \"Viral myositis\", section on 'Viral myositis with rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pyomyositis is a purulent infection of skeletal muscle that arises from hematogenous spread, usually with abscess formation. In healthy children, it is most commonly seen in tropical regions. Patients with pyomyositis in temperate zones more frequently are immunocompromised.",
"   </p>",
"   <p>",
"    Pyomyositis presents with fever and pain with cramping localized to a single muscle group. The disease occurs most often in the lower extremity (sites include the thigh, calf and gluteal muscles), but any muscle group can be involved, including the iliopsoas, pelvic, trunk, paraspinal, and upper extremity muscles. Multifocal infection with involvement of more than one muscle group may be observed in up to 20 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"     \"Pyomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Familial periodic paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abrupt onset of weakness in association with high, low, or normal serum potassium values is a rare form of familial paralysis that is inherited in an autosomal dominant fashion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=see_link\">",
"     \"Hypokalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Trichinellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichinellosis is caused by the ingestion of nematode cysts of the parasite Trichinella during the consumption of undercooked meat (eg, pork, wild bear). Approximately one week after eating the tainted meat, larvae enter skeletal muscles causing muscle pain, tenderness, swelling, and weakness. The pain can be so extreme as to limit all movement, including breathing or moving the tongue. High fever lasting a number of weeks is often seen and laboratory evaluation often reveals a marked eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=see_link\">",
"     \"Trichinellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Electrolyte disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness may indicate underlying hypokalemia, hypophosphatemia, hypocalcemia, hyponatremia, or hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Drug-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/21/10581?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/55/27512?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , and several chemotherapeutic agents) can cause weakness due to adverse effects on function of the peripheral nerve, neuromuscular junction, or muscle (",
"    <a class=\"graphic graphic_table graphicRef69751 \" href=\"UTD.htm?43/47/44798\">",
"     table 4",
"    </a>",
"    ). In addition chronic inhalant drug abuse with toluene containing agents, ingestion of sedative-hypnotics, muscle relaxants (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/5/26709?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    ), opioids, or drugs that can cause rhabdomyolysis (eg, amphetamines, phencyclidine) may cause significant muscle weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Conversion disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conversion disorder is defined as a symptom or deficit in voluntary motor function in patients without an anatomic or physiologic basis. In children, conversion disorder occurs more commonly in girls than boys and is most prevalent in children between the age of 10 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24425/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Risk factors include prior sexual abuse and preexisting psychiatric disease (eg, anxiety, depression). In children, symptoms are most commonly related to motor function and often start after an emotional stress or minor injury.",
"   </p>",
"   <p>",
"    In most cases, a detailed history identifies domestic stress (eg, parental divorce), feelings of parental rejection, unresolved grief,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    problems at school (eg, bullying, recent failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/54/24425/abstract/3\">",
"     3",
"    </a>",
"    ]. Physical examination often provides early diagnosis without extensive laboratory evaluation or ancillary studies. Key findings include reciprocal contraction during attempts to move apparently paralyzed muscle groups, presence of normal tendon reflexes in flaccid extremities, or physically implausible presentations (eg, triparesis). Successful treatment involves early referral for psychiatric care and avoidance of extensive investigation for an organic cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     CHRONIC MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many causes of chronic muscle weakness in children arise from congenital disorders that are apparent shortly after birth or in early childhood (",
"    <a class=\"graphic graphic_table graphicRef65108 \" href=\"UTD.htm?4/9/4252\">",
"     table 5",
"    </a>",
"    ). These include Erb palsy, congenital neuropathies, anterior horn cell disorders (eg, spinal muscular atrophy), congenital myopathies, muscular dystrophy, and inborn errors of metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=see_link\">",
"     \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities of the central nervous system, such as cerebral palsy or myelomeningocele (spina bifida), also result in chronic weakness or paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive subacute muscle weakness may be seen in children with an expanding brain tumor, Chiari malformation, tethered cord, dermatomyositis, prolonged heavy metal exposure (eg, arsenic), or neurodegenerative diseases (eg, metachromatic leukodystrophy, Alexander disease, Krabbe disease, and juvenile amyotrophic lateral sclerosis). (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Congenital hypothyroidism remains an important cause of muscle weakness in infants in many parts of the world. The Kocher-Debre-Semelaigne syndrome describes infants with typical features of cretinism associated with diffuse muscular hypertrophy and muscle weakness that is predominantly proximal. These infants have motor and cognitive developmental delay, constipation, myxedema, enlarged tongue, and coarse hair and skin typical of cretinism. Despite a very muscular, almost muscle-bound appearance, they are in fact weak and often have difficulty with sitting and head control. Neonatal screening has markedly reduced the number of infants with florid hypothyroidism. Screening of all newborns is now routine in the United States, Canada, Europe, Israel, Japan, Australia, and New Zealand, and is under development in Eastern Europe, South America, Asia, and Africa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypothyroid myopathy\", section on 'Congenital hypothyroidism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cushing's syndrome is another important and potentially reversible endocrine cause of chronic muscle weakness. In children, Cushing's syndrome most commonly arises from exogenous steroid administration and is frequently accompanied by striae, centripetal obesity, a \"buffalo hump\", steroid acne, and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic weakness may also rarely occur as a manifestation of a conversion disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several historical features help differentiate the cause of weakness in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing &ndash; Sudden, severe deterioration without trauma suggests subarachnoid hemorrhage, stroke, or brain tumor with hemorrhage. Subacute, chronic, or indolent presentations are more suggestive of neuropathies (eg, Guillain-Barr&eacute; syndrome) or myopathies (eg, muscular dystrophy). Weakness that worsens over the course of the day or preferentially affects the extraocular muscles is consistent with myasthenia gravis.",
"     </li>",
"     <li>",
"      Trauma &ndash; Weakness following trauma increases the concern for intracranial hemorrhage (eg, epidural hematoma) or spinal cord injury. Weakness immediately after birth would be concerning for nerve injury associated with childbirth (eg, Erb palsy).",
"     </li>",
"     <li>",
"      Seizure &ndash; Weakness in association with a seizure may indicate acute intracranial hemorrhage or stroke, but may also be caused by a self-limited Todd paralysis. Often, the child has a prior history of seizures with Todd paralysis. In addition, Todd paralysis should resolve within a few hours of the seizure.",
"     </li>",
"     <li>",
"      Headache &ndash; Headache and weakness, especially in children with progressive morning vomiting or focal neurological signs, is highly suggestive of an intracranial mass lesion. Children with an intracranial hemorrhage or stroke may also experience rapid onset of a severe headache, often described as the worst of their life. Weakness that is followed by a migrainoid headache is seen in children with hemisyndrome migraine.",
"     </li>",
"     <li>",
"      Neck or back pain &ndash; Patients with Guillain-Barr&eacute; syndrome, poliomyelitis, transverse myelitis, epidural hematoma, or epidural abscess often complain of neck or back pain.",
"     </li>",
"     <li>",
"      Fever &ndash; Fever is seen in patients with viral myositis, pyomyositis, and trichinellosis. In addition, a febrile illness may be a triggering stress in patients with acute intermittent porphyria.",
"     </li>",
"     <li>",
"      Exercise-induced &ndash; Weakness associated with exercise is characteristic of patients with myasthenia gravis, periodic paralysis, rhabdomyolysis, and myotonic dystrophy.",
"     </li>",
"     <li>",
"      Diet &ndash; Reef fish ingestion may lead to ciguatera poisoning. Paralytic shellfish poisoning occurs in patients who eat shellfish harvested from contaminated beds or during times of algae blooms known as red tides. Trichinellosis occurs in patients who consume undercooked pork or other contaminated meat (eg, wild bear meat). Outbreaks of food borne botulism usually involve consumption of home canned foods such as fruits, vegetables, and fish.",
"     </li>",
"     <li>",
"      Constipation &ndash; In infants, a history of constipation and poor feeding with generalized weakness suggests infant botulism.",
"     </li>",
"     <li>",
"      Dark urine &ndash; A history of dark red or brown urine should prompt consideration of rhabdomyolysis. Pigmenturia will be missed in rhabdomyolysis if the filtered load of myoglobin is insufficient or has largely resolved before the patient seeks medical attention.",
"     </li>",
"     <li>",
"      Medications and toxins &ndash; The clinician should identify any potential exposures to heavy metals (eg, arsenic, mercury, thallium), organophosphates, or medications known to cause weakness, such as corticosteroids (",
"      <a class=\"graphic graphic_table graphicRef69751 \" href=\"UTD.htm?43/47/44798\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical exam should first focus on the child's airway, breathing, and circulation. Many causes of weakness may lead to respiratory insufficiency and failure. Thus, the clinician should carefully assess respiratory effort, air movement, and pulse oximetry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of Cushing's triad (bradycardia, hypertension, and irregular respirations) or altered mental status should prompt evaluation for increased intracranial pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Muscle examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a patient complaining of muscle weakness, the examiner should follow a systematic approach that includes inspection of muscle, palpation and percussion of muscle, assessment of tone and manual muscle strength testing, and assessment of motor function. Joint examination and neurologic examination, including testing of the deep tendon reflexes and sensory testing, are important adjuncts to the muscle examination. Evaluation of muscle weakness in the adult is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29060?source=see_link\">",
"     \"Muscle examination in the evaluation of weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection &ndash; Muscle atrophy indicates chronic muscle disuse or denervation. Hypertrophy occurs in patients with Becker and Duchenne muscular dystrophy. Fasciculations suggest a lower motor neuron disorder (eg, spinal muscular atrophy). Ptosis is found in children with myasthenia gravis, botulism, and neurotoxic snake envenomation.",
"     </li>",
"     <li>",
"      Palpation and percussion &ndash; Muscle tenderness occurs in patients with myopathic weakness including those with myositis, trichinellosis, and rhabdomyolysis. Focal tenderness over the spine may be seen with epidural abscess or transverse myelitis.",
"     </li>",
"     <li>",
"      Tone and muscle strength testing in the infant &ndash; Tone is defined as the patient's passive resistance to movement. Tone in infants can be assessed by observing resistance of the upper or lower extremity as it is pulled by the examiner or by the pull-to-sit maneuver, in which the infant's hands are grasped and the baby is pulled from a supine to sitting position. The normal infant will offer some resistance, with flexion at the knees, elbows, and ankles. The head should move with the body and head lag should be minimal. Pronounced head lag may indicate hypotonia.",
"      <br/>",
"      <br/>",
"      Muscle strength also can be tested by holding the infant in a vertical position with the feet on a flat surface. A normal infant should be able to bear weight on the lower extremities while attempting to stand. In addition, infants with normal tone hold the wrist or ankle in line with the rest of the extremity. Strength is measured by examining the patient's active movement.",
"     </li>",
"     <li>",
"      Manual muscle strength testing in the older child &ndash; The Medical Research Council's grading system for muscle strength is widely used. The examiner assesses the patient's ability to move the muscle against resistance provided by the examiner who, through experience, has developed a sense of the expected range of normal motor function. This will vary from patient to patient depending upon the age of the subject (",
"      <a class=\"graphic graphic_table graphicRef66888 \" href=\"UTD.htm?16/39/17019\">",
"       table 6",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Decreased effort because of pain, fatigue, or malingering may be identified by \"give\" weakness in which there is initially a full effort followed by the abrupt loss of strength against resistance; this type of response does not occur in the truly weak individual. If intentionally decreased cooperation is suspected, observing the patient performing simple functional tasks such as sitting up from a supine position or toe or heel walking may reveal a discrepancy compared with the patient's performance on directed muscle strength testing.",
"     </li>",
"     <li>",
"      Muscle weakness patterns &ndash; The pattern of muscle weakness helps identify the underlying pathophysiology:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Generalized weakness is found in patients with myasthenia gravis, periodic paralysis, and organophosphate or carbamate poisoning, although some children with myasthenia gravis will have only ptosis or weakness confined to the cranial nerves.",
"     </li>",
"     <li>",
"      Asymmetric weakness (paraplegia or hemiplegia) is seen in patients with intracranial tumor or hemorrhage, stroke, hemisyndrome migraine, and spinal cord lesions.",
"     </li>",
"     <li>",
"      Symmetric weakness may be subdivided into proximal, distal, or regional weakness:",
"     </li>",
"     <li>",
"      Proximal weakness is characteristic for muscle disorders such as rhabdomyolysis, viral myositis, congenital myopathies, Duchenne muscular dystrophy, dermatomyositis, acute intermittent porphyria, and anterior cord syndrome following trauma or spinal vascular injury.",
"     </li>",
"     <li>",
"      Distal weakness suggests peripheral neuropathy (eg, Guillain-Barr&eacute; syndrome) or motor neuron disease, such as spinal motor atrophy or the congenital motor neuropathies (eg, juvenile amyotrophic lateral sclerosis).",
"     </li>",
"     <li>",
"      Regional weakness may be found adjacent to the feeding female tick in patients with tick paralysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to motor function, children with muscle weakness warrant a complete neurologic assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link\">",
"     \"Detailed neurologic assessment of infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings of particular importance include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ophthalmoplegia and other cranial nerve deficits are seen in patients with neuromuscular junction disorders such as botulism, myasthenia gravis, neurotoxic snake envenomation, and tick paralysis. They may also be seen in the Miller-Fisher variant of Guillain-Barr&eacute; syndrome.",
"     </li>",
"     <li>",
"      Patients with spinal cord disorders have loss of sensation below the level of the lesion and may have decreased rectal tone and, in boys, decreased or absent cremasteric reflexes.",
"     </li>",
"     <li>",
"      Sensory abnormalities, including neurogenic pain, are suggestive of peripheral nerve and spinal cord disorders.",
"     </li>",
"     <li>",
"      Unusual sensations, such as hot-cold temperature reversal, in association with a feeling that the teeth are loose, are found in patients with ciguatera poisoning.",
"     </li>",
"     <li>",
"      Sensation is intact in patients with neuromuscular junction disorders (eg, botulism, myasthenia gravis) and muscle disease (eg, congenital myopathy, muscular dystrophy, dermatomyositis).",
"     </li>",
"     <li>",
"      Cerebellar abnormalities (eg, ataxia, dysmetria, ulnar drift) suggest a central nervous system lesion.",
"     </li>",
"     <li>",
"      Deep tendon reflexes are typically diminished or absent in patients with Guillain-Barr&eacute; syndrome, botulism, spinal muscular atrophy, or tick paralysis. They are increased in patients with upper motor neuron lesions that are not acute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's skin should be searched for an engorged tick, especially in the scalp, at the hairline, and in gluteal fold.",
"   </p>",
"   <p>",
"    Skin findings of dermatomyositis include Gottron papules on the hands, facial heliotrope rash (",
"    <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"     picture 1",
"    </a>",
"    ), periungual capillary changes, and dystrophic calcification (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent ancillary studies in the weak child focus on assessment of respiratory status and identification of etiologies amenable to medical or surgical treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of respiratory function &ndash; Blood gas assessment, ancillary respiratory assessment tools (eg, SpO2, ETCO2), and pulmonary function testing (especially negative inspiratory force) aid in identifying subtle deterioration that may herald impending respiratory failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"       \"Overview of pulmonary function testing in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link&amp;anchor=H12584090#H12584090\">",
"       \"Simple and mixed acid-base disorders\", section on 'Respiratory acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolyte abnormalities &ndash; Electrolyte measurements may identify an electrolyte disturbance that is the primary cause of weakness or show abnormalities in potassium associated with rhabdomyolysis (hyperkalemia) or periodic paralysis (hypokalemia or hyperkalemia). An elevated creatine kinase is seen in patients with myositis, rhabdomyolysis, dermatomyositis, and other myopathies.",
"     </li>",
"     <li>",
"      Urinalysis &ndash; Urinalysis may show reddish brown pigment in patients with rhabdomyolysis and will have measurable myoglobin.",
"     </li>",
"     <li>",
"      Neuroimaging &ndash; Patients with focal muscle weakness suggestive of central or spinal cord lesions warrant appropriate neuroimaging. Emergent computed tomography of the brain should be performed in patients with suspected brain tumor, stroke, or intracranial hemorrhage. Emergent magnetic resonance imaging of the spine should be obtained in children with evidence of a spinal cord tumor, hematoma, or abscess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specialized electrophysiologic testing of muscle and nerve function for diagnostic purposes should be obtained in association with neurological consultation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a child with weakness depends on the acuity of the presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Sudden onset, severe weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of trauma followed by immediate weakness require prompt neuroimaging and consultation with a neurosurgeon in anticipation of an intracranial hemorrhage or spinal cord injury (",
"    <a class=\"graphic graphic_algorithm graphicRef53075 \" href=\"UTD.htm?42/38/43629\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Immediate onset weakness after a seizure requires close assessment for rapid improvement typically seen in patients with Todd paralysis. If weakness persists, then the possibility of a seizure in association with a stroke, subarachnoid hemorrhage, or brain tumor should be pursued.",
"   </p>",
"   <p>",
"    Rapid onset weakness in association with headache or other signs of increased intracranial pressure in the absence of trauma or seizure suggests the presence of stroke, subarachnoid hemorrhage, or brain tumor with hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Acute onset weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following considerations assist in identifying the cause of acute onset of weakness (within hours to days) (",
"    <a class=\"graphic graphic_algorithm graphicRef78154 \" href=\"UTD.htm?23/53/24400\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent seizure in a patient with proximal muscle weakness and tenderness of large muscle groups (rhabdomyolysis)",
"     </li>",
"     <li>",
"      Constipation, poor suck, and progressive weakness in an infant (infant botulism)",
"     </li>",
"     <li>",
"      Recent ingestion of barrier reef fish (eg, mahi-mahi), shellfish, undercooked pork, or home canned food (ciguatera poisoning, paralytic shellfish poisoning, trichinellosis, or botulism), or neurotoxic envenomation",
"     </li>",
"     <li>",
"      Exposure to medications (",
"      <a class=\"graphic graphic_table graphicRef69751 \" href=\"UTD.htm?43/47/44798\">",
"       table 4",
"      </a>",
"      ) known to cause weakness or to precipitate acute intermittent porphyria (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 2",
"      </a>",
"      ) or toxin exposure (eg, organophosphates, carbamates, heavy metals)",
"     </li>",
"     <li>",
"      Presence of fever (viral myositis, pyomyositis, trichinellosis)",
"     </li>",
"     <li>",
"      Headache (acute hemisyndrome migraine, brain tumor, stroke, subarachnoid hemorrhage)",
"     </li>",
"     <li>",
"      Neck or back pain (Guillain-Barr&eacute;, poliomyelitis, transverse myelitis, epidural hematoma or abscess)",
"     </li>",
"     <li>",
"      Attached engorged tick (tick paralysis) or infected wound (wound botulism)",
"     </li>",
"     <li>",
"      Presence of an inciting event or psychologic stress in concert with physical examination features suggestive of conversion disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Subacute or chronic weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should assess children with subacute or chronic weakness for signs of increased intracranial pressure (headache, morning vomiting, focal neurologic signs) that would indicate a brain tumor (",
"    <a class=\"graphic graphic_algorithm graphicRef51289 \" href=\"UTD.htm?38/57/39838\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients whose weakness is exacerbated by exercise should undergo additional evaluation for myasthenia gravis, periodic paralysis, myotonic dystrophy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rhabdomyolysis depending upon family history, physical findings, and laboratory studies.",
"   </p>",
"   <p>",
"    Gottron papules on the hands, facial heliotrope rash (",
"    <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"     picture 1",
"    </a>",
"    ), periungual capillary changes, and dystrophic calcification (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ) are findings of dermatomyositis in children.",
"   </p>",
"   <p>",
"    Weakness that is greater in the proximal muscle groups is typical for muscle disorders such as spinal muscular atrophy, muscular dystrophy, congenital myopathies, congenital hypothyroidism, or Cushing's syndrome. Of note, patients with spinal muscular atrophy have cranial nerve involvement with difficulty swallowing.",
"   </p>",
"   <p>",
"    Distal muscle weakness is more suggestive of a neurodegenerative process (eg, juvenile amyotrophic lateral sclerosis) or a chronic neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=see_link\">",
"     \"Overview of acquired peripheral neuropathies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to the child with muscle weakness is summarized in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef53075 \" href=\"UTD.htm?42/38/43629\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef78154 \" href=\"UTD.htm?23/53/24400\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef51289 \" href=\"UTD.htm?38/57/39838\">",
"     algorithm 3",
"    </a>",
"    ). Assessment should focus on key historical and physical examination findings that help narrow the extensive differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef81649 \" href=\"UTD.htm?35/18/36140\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H42\">",
"     'History'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H43\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tsarouhas N, Decker JM. Weakness. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.691.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24425/abstract/2\">",
"      Sweney MT, Silver K, Gerard-Blanluet M, et al. Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome. Pediatrics 2009; 123:e534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24425/abstract/3\">",
"      Leary PM. Conversion disorder in childhood--diagnosed too late, investigated too much? J R Soc Med 2003; 96:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/54/24425/abstract/4\">",
"      Spratt EG, Thomas SG. Pediatric case study and review: is it a conversion disorder? Int J Psychiatry Med 2008; 38:185.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6442 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24425=[""].join("\n");
var outline_f23_54_24425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H52\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Upper motor neuron weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lower motor neuron weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACUTE MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cerebral cortex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intracranial hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Brain tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Seizure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Alternating hemiplegia of childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Spinal cord",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Spinal cord trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Spinal cord tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Paraspinal infection or inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Transverse myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anterior horn cell disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Poliomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Peripheral Nerve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Peripheral nerve toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuromuscular junction disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Botulism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Organophosphate or carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Neurotoxic snake envenomation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Tick paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Muscle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Myositis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Familial periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Trichinellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Electrolyte disturbance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Drug-related",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Conversion disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      CHRONIC MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Muscle examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Other findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Sudden onset, severe weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Acute onset weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Subacute or chronic weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6442|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/38/43629\" title=\"algorithm 1\">",
"      Sudden weakness in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/53/24400\" title=\"algorithm 2\">",
"      Acute weakness in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/57/39838\" title=\"algorithm 3\">",
"      Chronic weakness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6442|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/57/37790\" title=\"figure 1\">",
"      Nerve toxicity of organophosphates and carbamates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6442|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/3/8243\" title=\"picture 1\">",
"      Rash - Juvenile dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/23/377\" title=\"picture 2\">",
"      Physical findings - Juvenile dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/18/36140\" title=\"table 1\">",
"      Muscle weakness child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43116\" title=\"table 2\">",
"      Acute porphyrias drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/23/18813\" title=\"table 3\">",
"      Organophosphate and carbamate poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/47/44798\" title=\"table 4\">",
"      Polyneuropathy drugs toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/9/4252\" title=\"table 5\">",
"      Chronic weakness child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/39/17019\" title=\"table 6\">",
"      Muscle strength test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=related_link\">",
"      Approach to the infant with hypotonia and weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=related_link\">",
"      Differential diagnosis of acute central nervous system demyelination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=related_link\">",
"      Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9193?source=related_link\">",
"      Hypokalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=related_link\">",
"      Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29464?source=related_link\">",
"      Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=related_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5962?source=related_link\">",
"      Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=related_link\">",
"      Marine toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29060?source=related_link\">",
"      Muscle examination in the evaluation of weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=related_link\">",
"      Overview of acquired peripheral neuropathies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=related_link\">",
"      Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3494?source=related_link\">",
"      Tick paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41781?source=related_link\">",
"      Treatment of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=related_link\">",
"      Viral myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_54_24426="Pemphigus vulgaris biopsy";
var content_f23_54_24426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60749%7EDERM%2F82837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60749%7EDERM%2F82837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic specimen of a bullous lesion in a patient with pemphigus vulgaris demonstrates the characteristic loss of cohesion between epidermal cells (acantholysis) with an intact basement membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris direct immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intercellular pattern of IgG antibody binding is evident on direct immunofluorescence in this specimen from a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24426=[""].join("\n");
var outline_f23_54_24426=null;
var title_f23_54_24427="Stepwise FM therapy";
var content_f23_54_24427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stepwise fibromyalgia therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial approach in every patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm the diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Education, explain the condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate and treat comorbidities, such as mood and sleep disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Most patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trial with low-dose tricyclic antidepressants or selected antidepressants or anticonvulsants proven effective in fibromyalgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients not responding to above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Specialty referral (eg, rheumatologist, physiatrist, psychiatrist, pain management)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combinations of drug therapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical therapy measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychological interventions, such as cognitive behavioral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multidisciplinary programs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292:2388.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24427=[""].join("\n");
var outline_f23_54_24427=null;
var title_f23_54_24428="Differential dx hyperamylasemia";
var content_f23_54_24428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hyperamylasemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predominant amylase isoform",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pancreatic disease",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute or chronic pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Post-ERCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudocyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatic ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute cholecystitis",
"       </td>",
"       <td>",
"        Pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intestinal diseases",
"       </td>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parotitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Calculi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy with ectopic amylase production",
"       </td>",
"       <td>",
"        Salivary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acidosis or ketoacidosis",
"       </td>",
"       <td>",
"        Salivary or pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure",
"       </td>",
"       <td>",
"        Salivary and pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macroamylasemia",
"       </td>",
"       <td>",
"        Macroamylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Fallopian tube diseases",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Salivary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ruptured ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Salpingitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Miscellaneous",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Salivary and/or pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcoholism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anorexia nervosa/bulimia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cirrhosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24428=[""].join("\n");
var outline_f23_54_24428=null;
var title_f23_54_24429="Formate and Cl transport";
var content_f23_54_24429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Formate and proximal chloride reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Role of filtered formate (F-) in active Cl- reabsorption in the proximal tubule. The essential steps are transport of uncharged formic acid (HF) into the cell, formate secretion and Cl- reabsorption via a formate-chloride exchanger, and recycling of formate into the cell as formic acid. Reabsorbed Cl- is returned to the peritubular capillary by a KCl cotransporter in the basolateral membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24429=[""].join("\n");
var outline_f23_54_24429=null;
var title_f23_54_24430="Doses pediatric resuscitation";
var content_f23_54_24430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic agents for pediatric advanced life support",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen",
"       </td>",
"       <td>",
"        All infants and children outside of the neonatal period",
"       </td>",
"       <td>",
"        100 percent initial dose via nonrebreathing face mask or bag-mask ventilation, wean as clinically indicated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        Documented blood glucose &lt;40 mg/dL (2.2 mmol/L)*",
"       </td>",
"       <td>",
"        0.5 to 1 gram/kg, IV or IO (eg, 2 to 4 mL/kg of 25 percent dextrose solution)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Epinephrine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Asystole",
"        </p>",
"        <p>",
"         Pulseless electrical activity",
"        </p>",
"        <p>",
"         Pulseless ventricular arrhythmias not responsive to initial defibrillation",
"        </p>",
"        <p>",
"         Bradycardia not responsive to oxygen and support of airway and breathing",
"        </p>",
"       </td>",
"       <td>",
"        0.01 mg/kg IV or IO given as 0.1 mL/kg of the 0.1 mg/mL (1:10,000) solution up to 1 mg per dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.1 mg/kg endotracheal (ET) given as 0.1 mL/kg of the 1 mg/mL (1:1000) solution up to 2.5 mg per dose diluted to 3 to 5 mL with saline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeat every 3 to 5 minutes as needed; not compatible with sodium bicarbonate",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Adenosine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Supraventricular tachycardia (SVT)",
"       </td>",
"       <td>",
"        Initial dose 0.1 mg/kg (children &gt;50 kg receive 6 mg) given as rapid IV or IO push closest to central circulation; follow immediately with 5 mL saline flush",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If not responsive in 2 minutes, give second dose of 0.2 mg/kg (children &gt;50 kg receive 12 mg); if not responsive after additional 2 minutes, give third dose of 0.3 mg/kg (maximum 12 mg)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Amiodarone",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Pulseless ventricular arrhythmias not responsive to defibrillation and epinephrine",
"        </p>",
"        <p>",
"         Stable ventricular tachycardia",
"        </p>",
"        <p>",
"         SVT refractory to adenosine",
"        </p>",
"       </td>",
"       <td>",
"        5 mg/kg rapid IV or IO bolus (maximum dose 300 mg) during cardiac arrest or over 20 to 60 minutes if perfusing rhythm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May repeat 5 mg/kg dose up to a maximum total daily dose of 15 mg/kg (total maximum 2.2 grams per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not for ET administration",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Procainamide",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Stable ventricular tachycardia",
"        </p>",
"        <p>",
"         SVT in patients with WPW syndrome or refractory to adenosine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bolus dose:",
"        </p>",
"        <p>",
"         - Infants and children &lt;1 year: 7-10 mg/kg IV or IO over 30 to 60 minutes",
"        </p>",
"        <p>",
"         - Children &ge;1 year: 15 mg/kg IV or IO over 30 to 60 minutes",
"        </p>",
"        <p>",
"         Maximum: 500 mg in 30 minutes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow bolus dose with a continuous infusion at 40-50 mcg/kg per minute (maximum 2 grams/24 hours) and obtain plasma levels 4 hours after loading dose",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Magnesium sulfate",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Polymorphic ventricular tachycardia (torsades de pointes)",
"        </p>",
"        <p>",
"         Documented hypomagnesemia",
"        </p>",
"       </td>",
"       <td>",
"        Dilute in 5 percent dextrose (D5W) to a solution that is 20 percent or less; 20 percent solution is 20 mg/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25 to 50 mg/kg (maximum dose 2 grams) IV or IO infusion over 1 to 2 minutes (pulseless arrest) or 15 minutes (perfusing patient)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Atropine",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Vagally mediated bradycardia",
"        </p>",
"        <p>",
"         Primary atrioventricular block",
"        </p>",
"        <p>",
"         Bradycardia not responsive to oxygen, airway support, and epinephrine administration",
"        </p>",
"        <p>",
"         Prevention of bradycardia during endotracheal intubation for children &lt;1 year of age, children 1-5 years of age receiving succinylcholine, and children over 5 years of age receiving a second dose of succinylcholine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.02 mg/kg IV or IO (minimum 0.1 mg",
"         <sup>",
"          ",
"         </sup>",
"         , maximum single dose 0.5 mg for child or 1 mg for adolescent); may repeat once in 3 to 5 minutes",
"        </p>",
"        <p>",
"         Maximum total dose 2 mg",
"         <sup>",
"          ",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.04-0.06 mg/kg ET diluted with 3 to 5 mL saline; repeat once if needed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Sodium bicarbonate",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Hyperkalemia",
"        </p>",
"        <p>",
"         Poisoning by sodium channel blocking agents (eg, cyclic antidepressants, type Ia antiarrhythmic agents) with prolongation of QRS interval (&gt;0.1 msec)",
"        </p>",
"        <p>",
"         Prolonged cardiac arrest with documented severe metabolic acidosis (routine use in resuscitation is NOT recommended)",
"        </p>",
"        <p>",
"         Shock with documented metabolic acidosis",
"        </p>",
"        <br/>",
"       </td>",
"       <td>",
"        1 mEq/kg slow IV or IO initial dose (1 mL/kg of 8.4 percent solution or, in infants under 6 months, 2 mL/kg of 4.2 percent solution)**; maximum single dose 50 mEq (child) to 100 mEq (adolescent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 mEq/kg subsequent doses after 10 minutes (0.5 mL/kg of 8.4 percent solution or, in infants under 6 months, 1 mL/kg of 4.2 percent solution);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not for ET administration",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Calcium chloride",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Hypocalcemia",
"        </p>",
"        <p>",
"         Hypermagnesemia",
"        </p>",
"        <p>",
"         Hyperkalemia",
"        </p>",
"        <p>",
"         Calcium channel blocker overdose",
"        </p>",
"       </td>",
"       <td>",
"        5 to 7 mg/kg ELEMENTAL calcium (eg, 0.2 mL/kg of calcium chloride 10 percent is 5.4 mg/kg ELEMENTAL calcium); maximum single dose is 540 mg ELEMENTAL calcium which is contained in 20 mL of calcium chloride 10 percent solution;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give as slow IV or IO push in pulseless patients and over 5 to 10 minutes in perfusing patients; may repeat in 10 minutes if needed;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral administration of calcium chloride not recommended**; see topic for calcium gluconate via peripheral IV for perfusing rhythm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not for ET administration",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; IO: intraosseous; ET: endotracheally.",
"     <br>",
"      * Routine administration of glucose without evaluation of the serum glucose is not recommended. Empiric treatment with glucose may be appropriate if bedside glucose determination is not available and the infant or child has symptoms of hypoglycemia or is at risk for developing hypoglycemia. (Refer to UpToDate topics on hypoglycemia in infants and children.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Care must be take to use the correct concentration (1:10,000 vs 1:1000).",
"       <br>",
"        &Delta; May cause atrial fibrillation with progression to ventricular fibrillation in children with Wolff-Parkinson-White syndrome. Avoid in children with wide complex tachycardia because severe hemodynamic deterioration may occur in patients with ventricular tachycardia. Early consultation with pediatric cardiologist is recommended.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Amiodarone should not be administered with other drugs that may cause QT prolongation (eg, procainamide) or patients with congenital long QT syndrome. Cardiology consult recommended prior to use when patient has a perfusing rhythym.",
"         <br>",
"          &sect; May be used safely in children with Wolff-Parkinson-White syndrome. Should not be used in patients who have received other drugs that prolong the QT interval (eg, amiodarone) or in patients with congenital prolonged QT syndrome.",
"          <br>",
"           &yen; Rapid infusions of magnesium sulfate in perfusing patients are associated with hypotension and asystole.",
"           <br>",
"            &Dagger; A weight based dose of 0.02 mg/kg atropine is used by some experts for infants and small children weighing less than 5 kg. (Refer to UpToDate topics on pediatric resuscitation drugs).",
"            <br>",
"             &dagger; Patients with poisoning from cholinesterase inhibiting agents may require much higher doses of atropine to dry bronchial secretions. (Refer to UpToDate topics on organophosphate and carbamate poisoning.)",
"             <br>",
"              ** Sodium bicarbonate should only be administered to children with adequate ventilation. Flush well with normal saline before and after administration to avoid alkaline inactivation of epinephrine or precipitation with calcium containing solutions.",
"              <br>",
"               <font class=\"double_bullet\">",
"                &bull;&bull;",
"               </font>",
"               Rapid administration can cause bradycardia or asystole. Calcium chloride should be given through central venous or intraosseous access, if possible to avoid potential skin necrosis or sloughing in the event of extravasation.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24430=[""].join("\n");
var outline_f23_54_24430=null;
var title_f23_54_24431="Nonopioid analgesic and NSAID table";
var content_f23_54_24431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected nonopioid analgesic and nonsteroidal antiinflammatory drugs (NSAIDs): Usual dosing for adults with pain or inflammation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose per day (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual analgesic dose and interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose per day (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Role in therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Para-aminophenol derivative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen* (paracetamol)",
"       </td>",
"       <td>",
"        &lt;2600",
"       </td>",
"       <td>",
"        325 to 1000 mg every 4 to 6 hours",
"       </td>",
"       <td>",
"        4000",
"       </td>",
"       <td>",
"        Treatment of mild pain and minor febrile conditions. Lacks significant antiinflammatory effect. Useful adjunct to opioid analgesics and NSAIDs. Lacks antiplatelet effect and gastrointestinal (GI) toxicity. Can cause hepatotoxicity in chronic or acute overdosage. Avoid, or use a lower daily dose, in older adults and patients at risk for hepatoxicity (eg, heavy alcohol use or malnourished). Interacts with warfarin (prolongation of INR) and CYP-450 inducing drugs (elevated risk of hepatic inflammation).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen intravenous",
"       </td>",
"       <td>",
"        &lt;2600",
"       </td>",
"       <td>",
"        650 mg every 4 hours or 1000 mg ever 6 hours, or 15 mg/kg every six hours for patients weighing &lt;50 kg",
"       </td>",
"       <td>",
"        4000; maximal daily dose 75 mg/kg if &lt;50 kg",
"       </td>",
"       <td>",
"        Short term treatment of mild to moderate acute pain and febrile conditions when oral administration is not available and as an adjunct to opiate analgesics for the treatment of moderate to severe pain. Patient should be well hydrated and dose reduced for hepatic or renal impairment. Not indicated for treatment of chronic cancer pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Non-selective nonsteroidal antiinflammatory (NSAID) agents",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Salicylate (acetylated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Aspirin*",
"       </td>",
"       <td>",
"        2600",
"       </td>",
"       <td>",
"        325 to 650 mg every 4 to 6 hours",
"       </td>",
"       <td>",
"        4000",
"       </td>",
"       <td>",
"        Standard for comparison but now used infrequently for treatment of chronic pain and inflammation due to its association with severe gastropathy. Unlike other NSAIDs, irreversibly inhibits platelet function for platelet life (7 to 10 days) and salicylism may occur with high doses or chronic use at analgesic doses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Salicylates (non-acetylated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diflunisal",
"       </td>",
"       <td>",
"        1000 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500 mg every 8 to 12 hours",
"       </td>",
"       <td>",
"        1500",
"       </td>",
"       <td rowspan=\"3\">",
"        All agents: Treatment of mild to moderate pain and acute or chronic inflammatory conditions. Relatively lower risk of gastropathy compared to aspirin and possibly other NSAIDs. Generally tolerated by patients with asthma. Slower onset and possibly longer duration of action than aspirin or acetaminophen. Do not inhibit platelet function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Choline magnesium trisalicylate",
"       </td>",
"       <td>",
"        1500 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        750 mg every 8 to 12 hours",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Salsalate",
"       </td>",
"       <td>",
"        1500",
"       </td>",
"       <td>",
"        750 to 1000 mg every 8 to 12 hours",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Propionic acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ibuprofen*",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        400 mg every 4 to 6 hours",
"       </td>",
"       <td>",
"        3200 acute, 2400 chronic",
"       </td>",
"       <td>",
"        Treatment of mild to moderate pain, minor fever and acute or chronic inflammatory conditions. A 200 to 400 mg dose is comparable in analgesic effect to 650 mg acetaminophen or aspirin. Reversibly inhibits platelet function and increases bleeding time. Can alter cardioprotective effect of low dose aspirin",
"        <sup>",
"         &loz;",
"        </sup>",
"        . Minimal risk of severe gastropathy with daily dose &le;2400 mg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ibuprofen (intravenous)",
"       </td>",
"       <td>",
"        1600",
"       </td>",
"       <td>",
"        400 to 800 mg every 6 hours",
"       </td>",
"       <td>",
"        3200 (acute)",
"       </td>",
"       <td>",
"        Short term treatment of mild to moderate acute pain and febrile conditions when oral administration is not available and as an adjunct to other analgesics for the treatment of moderate to severe postoperative pain. Patients should be well hydrated and without significant kidney disease. Not indicated for treatment of chronic cancer pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Naproxen*",
"       </td>",
"       <td>",
"        500 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (naproxen base)",
"       </td>",
"       <td>",
"        250 mg every 8 hours or 500 mg every 12 hours (naproxen base)",
"       </td>",
"       <td>",
"        1250 acute, 1000 chronic (naproxen base)",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Treatment of mild to moderate pain, minor fever and acute and chronic inflammatory conditions. 250 mg dose (base) comparable in analgesic effect to 650 mg aspirin.",
"        </p>",
"        <p>",
"         In the treatment of rheumatologic disorders, total daily dose may be increased to a maximum of 1500 mg base (1650 mg naproxen sodium) when needed for added effect.",
"        </p>",
"        <p>",
"         Reversibly inhibits platelet function and increases bleeding time. Can alter cardioprotective effect of low dose aspirin",
"         <sup>",
"          &loz;",
"         </sup>",
"         .",
"        </p>",
"        <p>",
"         Appears to have the greatest relative cardiovascular safety profile among nonselective COX-2 inhibitors.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        550 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (naproxen sodium)",
"       </td>",
"       <td>",
"        275 every 8 hours or 550 mg every 12 hours (naproxen sodium)",
"       </td>",
"       <td>",
"        1375 acute, 1100 chronic (naproxen sodium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ketoprofen*",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        25 to 50 mg every 6 to 8 hours",
"       </td>",
"       <td>",
"        300 mg",
"       </td>",
"       <td>",
"        For treatment of mild to moderate pain and acute or chronic inflammation. 25 mg dose comparable to analgesic effect of 400 mg ibuprofen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Flurbiprofen",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        50 to 100 mg every 6 to 12 hours",
"       </td>",
"       <td>",
"        300 mg",
"       </td>",
"       <td>",
"        For treatment of mild to moderate pain and acute or chronic inflammation. In some countries it is available as a lozenge for throat pain and as an intravenous injection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oxaprozin",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        26 mg/kg up to 1800 mg",
"       </td>",
"       <td>",
"        For treatment of chronic pain and inflammation, osteo- and rheumatoid arthritis. Once daily dosing may be useful.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Acetic acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diclofenac",
"       </td>",
"       <td>",
"        75 or 100 mg once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        50 mg every 8 hours",
"       </td>",
"       <td>",
"        150 mg",
"       </td>",
"       <td>",
"        For treatment of mild to moderate pain and acute or chronic inflammation. Also available as a topical patch for pain due to trauma and as a gel for treatment of painful joints.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Etodolac",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        200 to 400 mg every 6 to 8 hours",
"       </td>",
"       <td>",
"        1200 mg",
"       </td>",
"       <td>",
"        For treatment of mild to moderate pain and acute or chronic inflammation. 200 mg dose has a comparable analgesic effect to 400 mg of ibuprofen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Tolmetin",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        400 to 600 mg every 8 hours",
"       </td>",
"       <td>",
"        1800",
"       </td>",
"       <td>",
"        For treatment of chronic pain and inflammation, osteo- and rheumatoid arthritis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sulindac",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        150 to 200 mg every 12 hours",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        For treatment of acute and chronic pain and inflammatory conditions. More frequently implicated in hepatotoxicity than other NSAIDs. Parent drug and metabolites can accumulate with hepatic insufficiency. Drug and metabolites have been identified in renal calculi.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Indomethacin (indometacin)",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        <p>",
"         25 to 50 mg every 8 to 12 hours",
"        </p>",
"        <p>",
"         Controlled release: 75 mg every 12 hours",
"        </p>",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        An alternate, non first-line option for treatment of mild to moderate pain and acute or chronic inflammatory conditions. GI and central nervous system adverse effects may be more frequent or severe than with other NSAIDs. Intravenous formulation not indicated for pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" rowspan=\"2\">",
"        Ketorolac (intravenous and intramuscular)",
"       </td>",
"       <td>",
"        &lt;65 yrs 60 mg IV or IM once",
"       </td>",
"       <td>",
"        15 to 30 mg every 6 hours",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td rowspan=\"2\">",
"        Short term treatment of moderate acute pain when oral administration of an NSAID is not available and as an adjunct to other analgesics for the treatment of moderate to severe postoperative pain. Not indicated for treatment of chronic cancer pain. Risk of gastropathy is increased when use exceeds five days. An oral preparation of ketorolac is available but offers no advantage over other oral NSAIDs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;65 yrs 30 mg IV or IM once",
"       </td>",
"       <td>",
"        15 mg every 6 hours",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Oxicams (enolic acids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Meloxicam",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        7.5 to 15 mg every 24 hours",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        For treatment of chronic pain and inflammation, osteo- and rheumatoid arthritis. Once daily dosing may be useful. While reported to be selective for COX-2 at lower dose of 7.5 mg, overall adverse effects are similar to other NSAIDs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Piroxicam",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10 to 20 mg every 24 hours",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        An alternate, non first-line option for treatment of chronic pain and inflammation poorly responsive to other NSAIDs. Comparatively high incidence of gastropathy in daily dose above 20 mg and in older adults. Concurrent pharmacologic gastroprotection is suggested.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Fenamates (anthranilic acids)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Meclofenamate (meclofenamic acid)",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        50 mg every 4 to 6 hours",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        For treatment of acute or chronic pain and inflammation, osteo- and rheumatoid arthritis, dysmenorrhea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Mefenamic acid",
"       </td>",
"       <td>",
"        500 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        250 mg every 6 hours",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"       <td>",
"        For acute pain and dysmenorrhea. Anti-inflammatory efficacy is comparatively low. Not indicated for treatment of chronic cancer pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"5\">",
"        Non-acidic (naphthylalkanone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Nabumetone",
"       </td>",
"       <td>",
"        1000 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500 to 750 mg every 8 to 12 hours or 1000 to 1500 mg once daily",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        For treatment of chronic pain and inflammation, osteo- and rheumatoid arthritis. While reported to be comparatively selective for COX-2 at the lower dose of 500 mg twice daily, the overall adverse effects when dosed in the usual range are similar to the other NSAIDs. Once daily dosing may be useful.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Selective COX-2 inhibitors",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celecoxib",
"       </td>",
"       <td>",
"        400 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        200 mg daily or 100 mg every 12 hours",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        An option for patients requiring chronic NSAID treatment who may be at risk for gastropathy. Demonstrated efficacy and relative reduction in GI toxicity compared to non-selective NSAIDs. No effect on platelet function. Dosage above 200 mg daily associated with increased cardiovascular risk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etoricoxib",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        30 to 90 mg once daily",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        For treatment of acute and chronic pain and inflammation, osteo- and rheumatoid arthritis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parecoxib",
"        <sup>",
"         &yen;",
"        </sup>",
"        (intravenous and intramuscular)",
"       </td>",
"       <td>",
"        40 once",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        20 to 40 mg every 6 to 12 hours",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        For short-term treatment of postoperative pain where oral route of administration is not available. Not indicated for treatment of chronic cancer pain.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Doses are for adults, oral administration, except where noted otherwise.",
"    <div class=\"footnotes\">",
"     NSAID: nonsteroidal antiinflammatory drug.",
"     <br/>",
"     * Available without a prescription in US.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     NSAIDs may interact with aspirin, warfarin, methotrexate, anti-hypertensives, highly protein bound agents and other drugs. See \"NSAIDs: Therapeutic use and variability of response in adults\", section 'Drug interactions'. See Lexi-Interact for information on interaction of specific combinations of drugs.",
"     <br/>",
"     &Delta; Optional initial loading dose for pain or inflammation.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     See \"Nonselective NSAIDs: Cardiovascular effects\", section on 'Interference with beneficial effects of aspirin'.",
"     <br/>",
"     &sect; For additional information on gastroprotective strategies including selective COX-2 inhibitors and other options, see \"Overview of selective COX-2 inhibitors\" and \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\".",
"     <br/>",
"     &yen; Not available in US.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_54_24431=[""].join("\n");
var outline_f23_54_24431=null;
